NCT05271929
|
Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19 |
Not yet recruiting |
Phase 3 |
Mar/10/2022 |
Sep/10/2024 |
- Acronym - COVIC-19
- Alternative id -
COVIC-19
- Interventions -
Biological: COVID-19 convalescent and vaccinated plasma, Other: Current standard of care
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
CHU Besançon, Besançon, France; Klinikum Stuttgart, Stuttgart, Baden-Wuertemberg, Germany; Diakonie-Klinikum Stuttgart, Stuttgart, Baden-Wuertemberg, Germany; Uniklinikum Tübingen, Tübingen, Baden-Wuertemberg, Germany; Institut für Klinische Transfusionsmedizin (IKT), Ulm, Baden-Wuertemberg, Germany; Uniklinikum Ulm, Ulm, Baden-Wuertemberg, Germany; Universitätsklinikum Brandenburg, Brandenburg an der Havel, Brandenburg, Germany; Elblandkliniken Riesa, Riesa, Sachsen, Germany; Charité Medizinische Klinik IV, Berlin, Germany; NHS Blood and Transplant, Oxford, United Kingdom
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
680
- Age -
Child, Adult, Older Adult
- Outcome measures -
Proportion of participants with hospitalisation with O2 support or death, Proportion of participants with hospitalisation for progressive COVID-19 symptoms requiring O2 support, or death, Proportion of patients with hospitalisation and/or additional treatment for COVID-19, All-cause mortality, Proportion of patients with supplemental oxygen, Proportion of patients with non-invasive ventilation, Proportion of patients with intubation and mechanical ventilation, Change in 10-point WHO Clinical Progression Scale score, Duration of hospital admission censored at 28 days, Proportion of patients with admission to ITU, Duration of ITU admission censored at 28 days, Proportion of patients with long COVID-19 symptoms, Health-related quality of life assessed by EQ-5D quality of life index, Number of Serious Adverse Events, Number of Participants with arterial and venous thromboembolic events
|
NCT05077930
|
Convalescent Plasma Therapy for Hospitalized Patients With COVID-19 |
Recruiting |
Phase 2 |
Oct/01/2021 |
Jan/01/2022 |
- Alternative id -
CCP TRIAL
- Interventions -
Biological: Convalescent plasma, Drug: Standard of care
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Maternidade e Cirurgia Nossa Senhora do Rocio/ SA - Hospital do Rocio, Campo Largo, Paraná, Brazil
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
200
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Clinical status on a 7-point ordinal scale, Percentage of participants at each clinical status on a 7-point ordinal scale, Oxygen saturation, Prevalence of oxygen-intake methods, Respiratory rate, The PaO2 / FiO2 ratio (for patients on mechanical mechanisms), Number and /or extension of affected lung areas on chest computed tomography, Length of hospital stay, Length of stay in intensive care, Time until independence from oxygen therapy in days, Ventilator free days, In patients who needed mechanical ventilation, time to initiate mechanical ventilation (calculated in days, from entry into the protocol until orotracheal intubation), Rate of transfusion reactions to convalescent plasma infusion, Percentage of participants who develop serious adverse events and adverse events considered as definitely or probably associated with plasma transfusion
|
NCT04644198
|
Convalescent Plasma Transfusion in Severe COVID-19 Patients in Jamaica |
Recruiting |
Phase 2 |
Jun/01/2021 |
Dec/01/2021 |
- Alternative id -
ECP/195,19/20
- Interventions -
Biological: Convalescent Plasma Infusion
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
University of the West Indies, Kingston, Jamaica
- Study designs -
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
30
- Age -
18 Years to 65 Years (Adult, Older Adult)
- Outcome measures -
Mortality, Viral load, Antibody titre for Immunoglobulin (IgG) anti-SARS-CoV-2 antibody, Antibody titre for Immunoglobulin A (IgA) anti-SARS-CoV-2 antibody, Procalcitonin titres, Interleukin 6 (IL-6), D-dimer, C-reactive protein, Ferritin, Length of ICU admission, Days to recovery
|
NCT04884477
|
COVID-19 Infection in Patients Receiving Anti-CD20 Therapy |
Active, not recruiting |
|
Jun/01/2021 |
Jun/30/2022 |
- Alternative id -
21-001374
- Interventions -
Biological: Convalescent Plasma
- Study type - Observational
- Study results -
No Results Available
- Study locations -
Mayo Clinic, Rochester, Minnesota, United States
- Study designs -
Observational Model: Cohort, Time Perspective: Retrospective
- Enrollment -
342
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Change in WHO Clinical Progression scale, 90-day mortality, ICU-free days
|
NCT04954937
|
Convalescent Plasma Donor Vaccine Study An Observational Antibody Level Study. |
Recruiting |
|
Apr/20/2021 |
Apr/20/2022 |
- Acronym - C-VELVET
- Alternative id -
21AS0001
- Study type - Observational
- Study results -
No Results Available
- Study locations -
NHSBT - Birmingham Donation Centre, Birmingham, United Kingdom
- Study designs -
Observational Model: Other, Time Perspective: Prospective
- Enrollment -
100
- Age -
17 Years to 66 Years (Child, Adult, Older Adult)
- Outcome measures -
Increase in antibody levels post-vaccination assessed via Euroimmun assay, Increase in antibody levels post-vaccination assessed via Roche IgG assay, Increase in antibody levels post-vaccination assessed vial live virus neutralization
|
NCT04836260
|
Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19 |
Recruiting |
Phase 3 |
Apr/08/2021 |
Dec/31/2021 |
- Alternative id -
2020-02989
- Interventions -
Drug: SARS-CoV-2 convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Universitätsspital Basel, Basel, Switzerland; HFR-Fribourg Hôpital Cantonal, Fribourg, Switzerland; Geneva University Hospitals, Geneva, Switzerland; Ospedale Regionale di Lugano, Lugano, Switzerland
- Study designs -
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Prevention
- Enrollment -
100
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Proportion of patient that progress to WHO 8 ordinal scale ≥ 4 (oxygen requirement), Proportion of death, Proportion of patients with cleared nasopharyngeal viral load
|
NCT04390503
|
Convalescent Plasma for Early Treatment of COVID-19 |
Recruiting |
Phase 2 |
Mar/12/2021 |
Apr/01/2022 |
- Alternative id -
AAAT0052
- Interventions -
Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma), Biological: Control (albumin 5%)
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
National Institute of Infectious Diseases Evandro Chagas (INI), Rio de Janeiro, Brazil
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double (Participant, Outcomes Assessor), Primary Purpose: Treatment
- Enrollment -
150
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Rate of Severe Disease, Rate of measurable anti-SARS-CoV-2 titers, Rate of SARS-CoV-2 PCR Positivity, Duration of SARS-CoV-2 PCR Positivity, Levels of SARS-CoV-2 RNA
|
NCT04769245
|
The Effectiveness of ACB-IP 1.0 Convalescent Plasma in COVID-19 Infection |
Recruiting |
|
Feb/18/2021 |
Jun/01/2021 |
- Alternative id -
Acibadem Healthcare Group
- Study type - Observational
- Study results -
No Results Available
- Study locations -
Acıbadem Labcell Cellular Therapy Laboratories, Istanbul, Turkey; Acibadem Altunizade Hospital, Istanbul, Turkey
- Study designs -
Observational Model: Case-Only, Time Perspective: Retrospective
- Enrollment -
40
- Age -
18 Years to 75 Years (Adult, Older Adult)
- Outcome measures -
Mortality Rate, Length of Hospitalization, Side Effects
|
NCT04730401
|
Convalescent Plasma in the Treatment of Covid-19 |
Recruiting |
Phase 2 |
Jan/27/2021 |
Dec/31/2021 |
- Acronym - CP_COVID-19
- Alternative id -
Plasma_Covid-19
- Interventions -
Biological: Convalescent plasma from COVID-19 donors, Biological: Placebo
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Helsinki University Central Hospital, Helsinki, Uusimaa, Finland
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Triple (Participant, Care Provider, Investigator), Primary Purpose: Treatment
- Enrollment -
390
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Safety (SAE), Rate of intubation, Number of participants initiating systemic corticosteroids, Hospital stay, Mortality, ICU stay, Ventilator days, Severity of respiratory failure, Viral load, Antibody measurements, Thrombotic complication, The rate of participants presenting with coagulopathy disorders, Number of participants with laboratory change, Adverse effects, Convalescent plasma efficacy, Convalescent plasma high vs low titer efficacy, Convalescent plasma efficacy according to donor status
|
NCT04712344
|
Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO) |
Recruiting |
Phase 2 |
Jan/18/2021 |
Sep/01/2021 |
- Acronym - IPCO
- Alternative id -
UKER-COV2-01
- Interventions -
Biological: COVID-19 convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
University Hospital Erlangen, Erlangen, Germany
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
58
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Change in SOFA score from Baseline Visit, Assessment of impact of immune therapy with COVID-19 convalescent plasma on markers for ARDS due to severe COVID-19 infection, Assessment of impact of immune therapy with COVID-19 convalescent plasma on short-term all-cause mortality, Assessment of impact of immune therapy with COVID-19 convalescent plasma on oxygen supply in patients with ARDS due to severe COVID-19, Assessment of impact of immune therapy with COVID-19 convalescent plasma on oxygen demand in patients with ARDS due to severe COVID-19, Assessment of impact of immune therapy with COVID-19 convalescent plasma on Duration of Oxygen supply in patients with ARDS due to severe COVID-19, Assessment of impact of immune therapy with COVID-19 convalescent plasma on PEEP in patients with ARDS due to severe COVID-19, Assessment of impact of immune therapy with COVID-19 convalescent plasma on FiO2 in patients with ARDS due to severe COVID-19, Assessment of impact of immune therapy with COVID-19 convalescent plasma on driving pressure in patients with ARDS due to severe COVID-19, Assessment of impact of immune therapy with COVID-19 convalescent plasma on Duration of invasive mechanical Ventilation in patients with ARDS due to severe COVID-19
|
NCT04681430
|
Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals |
Completed |
Phase 2 |
Jan/08/2021 |
Oct/29/2021 |
- Acronym - RES-Q-HR
- Alternative id -
RES-Q-HR, 2020-004695-18
- Interventions -
Biological: Convalescent plasma, Drug: Camostat Mesilate, Drug: Placebo for Camostat Mesilate, Other: Standard of Care (SoC)
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Abteilung Infektiologie Klinik für Innere Medizin II Department Innere Medizin Universitätsklinikum Freiburg, Freiburg im Breisgau, Baden-Württemberg, Germany; Klinik und Poliklinik für Innere Medizin II Klinikum rechts der Isar Technische Universität München, München, Bavaria, Germany; Universitätsklinikum Frankfurt Medizinische Klinik 2: Hämatologie, Onkologie, Hämostaseologie, Rheumatologie, Infektiologie/HIV, Frankfurt am Main, Hessen, Germany; Universitätsklinikum Düsseldorf Klinik für Hepatologie und Infektiologie, Duesseldorf, North Rhine Westphalia, Germany; Klinikum Dortmund, Dortmund, North Rhine-Westphalia, Germany; Universitätsklinikum Essen, Essen, North Rhine-Westphalia, Germany
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor), Primary Purpose: Treatment
- Enrollment -
22
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
WHO ordinal Covid-19 scale up to day 28, Cumulative number WHO categories 4b-8, Cumulative number WHO categories 3-4a, Not hospitalized, All-cause mortality, Reinfection, Secondary sclerosing cholangitis (SSC), chronic pulmonary disease as sequelae from COVID-19, patients with remdesivir treatment, COVID-19 WHO status of patients at start of remdesivir treatment, patients with dexamethasone treatment, COVID-19 WHO status of patients at start of dexamethasone treatment, resolution of COVID-19 symptoms, negative SARS-CoV-2-PCR test, Oxygen therapy, COVID-19 pneumonia, Percentage of participants requiring mechanical ventilation, Number of ventilation days per participant up to day 90, hospital stay and intensive care, Mortality, SAEs, Grade 3/4 AEs, SARS-CoV-2 antibody IgA concentrations, SARS-CoV-2 antibody IgG concentrations, SARS-CoV-2 neutralizing antibody titers, Plasma treatment screening failures
|
NCT04528368
|
Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support |
Recruiting |
Phase 2 |
Dec/11/2020 |
Jan/30/2022 |
- Alternative id -
34651120.8.0000.5249
- Interventions -
Biological: Convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
D'Or Institute for Research and Education, Rio de Janeiro, Brazil
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
60
- Age -
Child, Adult, Older Adult
- Outcome measures -
Area under the curve of SARS-COV-2 viral load obtained from nasopharyngeal and /or oropharyngeal swabs., Assessment of clinical improvement using an Ordinal Severity Scale, Evaluate oxygen saturation, Evaluate oxygen supplementation, Assess respiratory rate, Evaluate the PaO2 / FiO2 ratio (for patients on mechanical mechanisms), Length of hospital stay, Length of stay in intensive care, Assess the rate of orotracheal intubation, Change in the profile of cytokines/chemokines in both groups, Presence of antibodies against SARS-CoV-2 in serum after convalescent plasma administration, Death rate, Rate of transfusion reactions to convalescent plasma infusion
|
NCT04649879
|
Convalescent Plasma for Treatment of COVID-19 |
Completed |
Phase 2|Phase 3 |
Dec/03/2020 |
Jan/26/2022 |
- Alternative id -
CP3
- Interventions -
Biological: SARS-CoV-2 convalescent plasma, Other: Standard of care
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Department of Infectious Disease, Falu Hospital, Falun, Dalarn, Sweden; Department of Geriatrics, Karolinska University Hospital, Stockholm, Sweden; Danderyd Hospital, Stockholm, Sweden
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
59
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
COVID-19 related mortality within 28 days, COVID-19 related mortality within 60 days, Requirement of invasive ventilation or Pao2/FiO2 ≤ 70 for ≥ 12 hours in the case of patients not eligible for intensive care, Adverse events, Dose of plasma needed to clear viremia, Time to clearance of viremia
|
NCT04642014
|
Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Evaluation of Therapy Effectiveness |
Not yet recruiting |
Not Applicable |
Dec/01/2020 |
May/01/2022 |
- Acronym - EPIC-19
- Alternative id -
2020.ABM.COVID19.0005
- Interventions -
Biological: COVID-19 convalescent plasma treatment
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Wroclaw Medical University, Wroclaw, Dolnośląskie, Poland
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
500
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Death, for any reason, For patients with respiratory support, the time to take one's own breath (extubation), Stay in the intensive care unit (ICU), Time to disconnect CPAP respiratory support, Time to elimination of SARS-Cov-2 (RT-PCR), Time to serological response (anti-SARS-COv-2 antibodies)
|
NCT04873414
|
Convalescent Plasma as Adjunct Therapy for COVID-19 |
Recruiting |
Phase 2|Phase 3 |
Dec/01/2020 |
Dec/31/2021 |
- Acronym - PlaSenTer
- Alternative id -
COVID-CT002
- Interventions -
Biological: Convalescent plasma treatment
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Aceh Tamiang Hospital, Aceh Tamiang, Aceh, Indonesia; Sanglah Central Hospital, Denpasar, Bali, Indonesia; Udayana University Hospital, Denpasar, Bali, Indonesia; Dr. Soeradji Tirtonegoro Hospital, Klaten, Central Java, Indonesia; Dr. Wongsonegoro Regency Hospital, Semarang, Central Java, Indonesia; Pasar Minggu Hospital, Jakarta, DKI, Indonesia; Dr. Haryoto Regency Hospital, Lumajang, East Java, Indonesia; Waluyo Jati Kraksaan Regency Hospital, Probolinggo, East Java, Indonesia; Sidoarjo Regency Hospital, Sidoarjo, East Java, Indonesia; Dr Ramelan Navy Hospital, Surabaya, East Java, Indonesia; Dr. Soetomo Hospital, Surabaya, East Java, Indonesia; Emergency Hospital for COVID-19 - Wisma Atlet Kemayoran, Jakarta Pusat, Jakarta, Indonesia; Prof. Dr. R.D. Kandou Hospital, Manado, North Sulawesi, Indonesia; Dr. Tadjuddin Chalid Hospital, Makassar, Souh Sulawesi, Indonesia; Dr. Wahidin Sudirohusodo Central Hospital, Makassar, South Sulawesi, Indonesia; Hasanuddin University Hospital, Makassar, South Sulawesi, Indonesia; Dadi Hospital, Makassar, South Sulawesi, Indonesia; Dr. Mohammad Hoesin Central Hospital, Palembang, South Sumatra, Indonesia; Dr. Hasan Sadikin Central Hospital, Bandung, West Java, Indonesia; RSD Gunung Jati, Cirebon, West Java, Indonesia; Gatot Soebroto Central Army Hospital, Jakarta Pusat, Indonesia; dr. Cipto Mangunkusumo National Central General Hospital, Jakarta, Indonesia; YARSI Hospital, Jakarta, Indonesia; Dr. Suyoto Pusrehab Kemenhan Hospital, Jakarta, Indonesia; Persahabatan Central hospital, Jakarta, Indonesia; Fatmawati Central Hospital, Jakarta, Indonesia; Prof. Dr. Sulianti Saroso Infectious Disease Hospital, Jakarta, Indonesia; University Of Indonesia Hospital (RSUI), Jakarta, Indonesia
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
364
- Age -
18 Years to 60 Years (Adult)
- Outcome measures -
The mortality in COVID-19 patients treated with convalescent plasma, Change in clinical status category in CP-receiving patients, Duration of hospitalization, Duration of mechanical ventilation, Duration of ICU stay, Change in lung image radiography in CP-receiving patients, Change in inflammatory parameters in CP-receiving patients, Change in coagulation parameters in CP-receiving patients, Change in viral load in CP-receiving patients, Changes in anti-SARS-CoV-2 antibody levels in CP-receiving patients, Systemic organ involvement in patients receiving CP treatment, Time to resolution of symptoms in patients receiving CP treatment, Treatment-related adverse events (AEs) and serious adverse events (SAEs), Impact of anti-SARS-CoV-2 antibody levels in donors on the efficacy of CP therapy in CP-receiving patients, Impact of anti-SARS-CoV-2 antibody levels in donors on the viral clearance in CP-receiving patients
|
NCT04521036
|
Convalescent Plasma for COVID-19 Patients (CPCP) |
Not yet recruiting |
Phase 1|Phase 2 |
Dec/01/2020 |
Oct/30/2021 |
- Acronym - CPCP
- Alternative id -
ISC.20.11.2
- Interventions -
Biological: Convalescent Plasma as Therapy for Covid-19 patients
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
44
- Age -
18 Years to 75 Years (Adult, Older Adult)
- Outcome measures -
Change in mortality, Change in requirement for mechanical ventilation, Change in the duration of mechanical ventilation, Incidence of Treatment-Emergent Adverse Events
|
NCT04669990
|
Remdesivir and Convalescent Plasma Therapy for Treatment of COVID-19 Infection in Nepal : A Registry Study |
Recruiting |
|
Nov/19/2020 |
Nov/19/2021 |
- Alternative id -
749-2020
- Interventions -
Drug: Remdesivir
- Study type - Observational
- Study results -
No Results Available
- Study locations -
Narayani Hospital, Birgunj, Nepal; Seti Provincial Hospital, Dhangadi, Nepal; BP Koirala Institute of Health Sciences (BPKIHS), Dharān Bāzār, Nepal; Bheri Provincial Hospital, Nepalgunj, Nepal
- Study designs -
Observational Model: Case-Only, Time Perspective: Prospective
- Enrollment -
2000
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Demographics of recipients, Co-morbidity of recipient, Adverse events of convalescent COVID-19 plasma and Remdesivir Therapy, Hospital and ICU length of stay, Disposition of patients including survival
|
NCT04634422
|
Plasma Exchange (PLEX) and Convalescent Plasma (CCP) in COVID-19 Patients With Multiorgan Failure |
Recruiting |
Not Applicable |
Nov/16/2020 |
Jun/30/2022 |
- Acronym - COVID-PLEX
- Alternative id -
H-20041716
- Interventions -
Procedure: Plasma exchange and convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Rigshospitalet, Copenhagen, Denmark
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
220
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Alive at Day 90th, Day 8 serious adverse events, Day 28 all cause mortality, Days alive without life support at day 90
|
NCT04539275
|
COVID-19 (VA CURES-1) |
Terminated |
Phase 3 |
Nov/16/2020 |
Sep/30/2021 |
- Acronym - VA CURES-1
- Alternative id -
COVID19-8900-22
- Interventions -
Drug: Convalescent Plasma, Other: Masked Saline Placebo
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama, United States; Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona, United States; Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado, United States; North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States; Orlando VA Medical Center, Orlando, FL, Orlando, Florida, United States; James A. Haley Veterans' Hospital, Tampa, FL, Tampa, Florida, United States; Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States; Edward Hines Jr. VA Hospital, Hines, IL, Hines, Illinois, United States; VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States; John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan, United States; VA Southern Nevada Healthcare System, North Las Vegas, NV, North Las Vegas, Nevada, United States; James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States; Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States; Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, United States; Oklahoma City VA Medical Center, Oklahoma City, OK, Oklahoma City, Oklahoma, United States; VA Portland Health Care System, Portland, OR, Portland, Oregon, United States; Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States; VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas, United States; Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States; South Texas Health Care System, San Antonio, TX, San Antonio, Texas, United States; VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States; Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia, United States; William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin, United States; VA Caribbean Healthcare System, San Juan, PR, San Juan, Puerto Rico
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Triple (Participant, Care Provider, Investigator), Primary Purpose: Treatment
- Enrollment -
75
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Proportion of participants developing acute hypoxemic respiratory failure or all-cause death, Time (in days) to recovery, Time (in days) to death or respiratory failure, Proportion of patients who died from any cause, had respiratory failure, or required humidified heated high-flow nasal cannula (HHHFNC) at 15 Lpm, Time (in days) to death or respiratory failure or HHHFNC at 15 Lpm, Subject 28-day all-cause mortality, Time to an improvement of one category using an ordinal scale, Time to an improvement of two categories using an ordinal scale, Participant's clinical status by ordinal scale, Mean change in the ordinal scale, Time to discharge or to a National Early Warning Score (NEWS)-2 of = 2 and maintained for 24 hours, whichever occurs first, Change in NEWS-2 Score from Day 1 (baseline) to Days 2, 4, 7, 11, 15, and 29, Duration of hospitalization, Number of hospitalizations related to COVID-19, Cumulative incidence of Serious Adverse Events (SAEs), Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs), Incidence of discontinuation or temporary suspension of study product administrations (for any reason), Change from baseline in hemoglobin, Change from baseline in platelets, Change from baseline in creatinine, Change from baseline in glucose, Change from baseline in total bilirubin, Change from baseline in alanine transaminase (ALT), Change from baseline in aspartate transaminase (AST), Change from baseline in prothrombin time (PT)
|
NCT04456413
|
Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection |
Recruiting |
Phase 2 |
Nov/06/2020 |
Nov/01/2023 |
- Alternative id -
Pro2020-0542
- Interventions -
Biological: Convalescent Plasma, Other: Best Supportive Care
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Hackensack University Medical Center, Hackensack, New Jersey, United States
- Study designs -
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
306
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Hospitalization Rate, Time to symptoms resolution, Overall survival, Rate of virologic clearance by nasopharyngeal swab at 2 and 4 weeks, Rate of nasopharyngeal swab positivity in donors, Rate of donor titers level, Impact of donor titers level on efficacy, Patients' anti-SARS-CoV2 titer assessment pre-infusion for the Treatment group, at 2 weeks , 4 weeks and 2 months.
|
NCT04764747
|
Effectiveness of Convalescent Plasma in Hospitalized Patients With COVID-19 |
Completed |
|
Nov/01/2020 |
Apr/25/2021 |
- Alternative id -
CP in COVID-19 patients
- Study type - Observational
- Study results -
No Results Available
- Study locations -
Al-Amal Hospital, Najaf, Iraq; Al-Hakeem Hospital, Najaf, Iraq
- Study designs -
Observational Model: Cohort, Time Perspective: Retrospective
- Enrollment -
400
- Age -
18 Years to 95 Years (Adult, Older Adult)
- Outcome measures -
Time to clinical improvement, Find the prediction factors associated with good outcome of patients on CP therapy, Time to negative PCR, Mortality rate, Hospital stay time, Adverse effect of plasma therapy
|
NCT04589949
|
Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study) |
Recruiting |
Phase 3 |
Oct/12/2020 |
Nov/01/2023 |
- Acronym - CoV-Early
- Alternative id -
NL74972.078.20
- Interventions -
Biological: ConvP, Biological: FFP
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands; Meander Medisch Centrum, Amersfoort, Netherlands; Rijnstate Ziekenhuis, Arnhem, Netherlands; Amphia Ziekenhuis, Breda, Netherlands; Groene Hart Ziekenhuis, Gouda, Netherlands; University Medical Center Groningen (UMCG), Groningen, Netherlands; Spaarne Gasthuis, Haarlem, Netherlands; Medisch Centrum Leeuwarden, Leeuwarden, Netherlands; Leids Universitair Medisch Centrum, Leiden, Netherlands; Sint Antonius Ziekenhuis, Nieuwegein, Netherlands; Bernhoven Hospital, Uden, Netherlands
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor), Primary Purpose: Treatment
- Enrollment -
690
- Age -
50 Years and older (Adult, Older Adult)
- Outcome measures -
Highest disease status, Percentage of deaths, Percentage of hospital admissions, Percentage of ICU admissions, Disease duration in days of symptoms, Age and clinical frailty score
|
NCT04377568
|
Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children |
Withdrawn |
Phase 2 |
Oct/07/2020 |
May/01/2022 |
- Acronym - CONCOR-KIDS
- Alternative id -
1000070143
- Interventions -
Biological: Convalescent plasma (CP)
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Alberta Children's Hospital, Calgary, Alberta, Canada; Stollery Children's Hospital, Edmonton, Alberta, Canada; BC Children's Hospital, Vancouver, British Columbia, Canada; Winnipeg Children's Hospital, Winnipeg, Manitoba, Canada; IWK Health Centre, Halifax, Nova Scotia, Canada; McMaster Children's Hospital, Hamilton, Ontario, Canada; Kingston Health Sciences Centre, Kingston, Ontario, Canada; Children's Hospital, London, Ontario, Canada; Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada; The Hospital for Sick Children, Toronto, Ontario, Canada; CHU Sainte-Justine, Montréal, Quebec, Canada; McGill Univ Health Ctr - Montreal Children's Hospital, Montréal, Quebec, Canada; Jim Pattison Children's Hospital, Saskatoon, Saskatchewan, Canada
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Age -
up to 18 Years (Child, Adult)
- Outcome measures -
Clinical recovery, Combined mortality/intubation, Respiratory status-1, Respiratory status-2, Respiratory status-3, respiratory status -4, respiratory status -5, respiratory status-6, Mortality 1a, Mortality 1b, Mortality 2a, Mortality 2b, Care and Critical Care, organ systems: renal, organ systems: cardiac, Transfusion-associated adverse events (AE), Safety of the intervention, organ systems: multi-system inflammatory disease
|
NCT04467151
|
Administration of Anti-SARS-CoV-2 Convalescent Plasma in Hospitalized, Non-ICU Patients With COVID-19 |
Withdrawn |
Phase 2 |
Oct/01/2020 |
Dec/01/2021 |
- Alternative id -
HS-20-00516
- Interventions -
Drug: anti-SARS-CoV-2 plasma, Other: Placebo
- Study type - Interventional
- Study results -
No Results Available
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Triple (Participant, Investigator, Outcomes Assessor), Primary Purpose: Treatment
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Disease progression measured by WHO scale, Comparison of maximum WHO score per group, Comparison of decrease of median and maximum WHO score per group, Comparison of time to clinical improvement per group, Comparison of time to reach score of "6" or greater on the WHO scale
|
NCT04497324
|
PERUCONPLASMA: Evaluating the Use of Convalescent Plasma as Management of COVID-19 |
Completed |
Phase 2 |
Sep/21/2020 |
Apr/17/2021 |
- Alternative id -
PER-016-20, 20997
- Interventions -
Biological: Convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Hospital Cayetano Heredia, Lima, Peru; Hospital Nacional Hipolito Unanue, Lima, Peru
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
100
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Transfusion-related Serious Adverse Events, All-cause in-hospital mortality, Length of hospital stay, Length of ICU stay, Need of invasive mechanical ventilation, Duration of mechanical ventilation, Clinical Improvement at 14 days
|
NCT04567173
|
Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19 |
Recruiting |
Phase 2|Phase 3 |
Sep/21/2020 |
Jun/30/2021 |
- Acronym - Co-CLARITY
- Alternative id -
PHRR200824-002868
- Interventions -
Drug: Anti-SARS-CoV-2 convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
UP Philippine General Hospital, Manila, Philippines
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
136
- Age -
19 Years and older (Adult, Older Adult)
- Outcome measures -
Incidence of serious adverse events, Quick SOFA (qSOFA) score, Cardiopulmonary arrest, ICU mortality, ICU length of stay, Hospital mortality, Hospital length of stay, Dialysis-free days, Vasopressor-free days, ICU-free days, 28-day mortality, Anti-SARS-CoV-2 antibody titers, SARS-CoV-2 RNA by RT-PCR
|
NCT04516811
|
Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19 |
Recruiting |
Phase 3 |
Sep/21/2020 |
Jul/31/2022 |
- Alternative id -
PROTECT-Patient trial
- Interventions -
Biological: COVID-19 convalescent plasma (CCP) plus standard of care (SOC), Biological: Standard of care (SOC) plus placebo
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Universitas Hospital, Bloemfontein, Free State, South Africa; Mitchells Plain Hospital, Cape Town, Western Cape, South Africa
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Triple (Participant, Care Provider, Investigator), Primary Purpose: Treatment
- Enrollment -
600
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Clinical Improvement, Adverse Events of special interest, Serious Adverse Events, Survival, Invasive mechanical ventilation, Disease severity, Time to outcomes of interest, Length of stay meausures, SARS-CoV PCR, Inflammatory markers, Radiography, Fever & Hypoxia, patients with HIV infection and other comorbidities, Timing of IP & Efficacy Outcome, Neutralising Ab, SARS CoV Antibody titre
|
NCT04372979
|
Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients. |
Recruiting |
Phase 3 |
Sep/14/2020 |
Jun/01/2021 |
- Acronym - PLASCOSSA
- Alternative id -
2020-A01166-33
- Interventions -
Drug: Transfusion of SARS-CoV-2 Convalescent Plasma., Drug: Transfusion of standard Plasma.
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
HIA Percy, Clamart, France; HIA Laveran, Marseille, France; HIA Bégin, Saint-Mandé, France; HIA Sainte Anne, Toulon, France
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Triple (Participant, Investigator, Outcomes Assessor), Primary Purpose: Treatment
- Enrollment -
80
- Age -
18 Years to 90 Years (Adult, Older Adult)
- Outcome measures -
Survival time without needs of a ventilator., Morbidity, Mortality, Length of stay, Effect on viral pharyngeal specimen clearance, Effect on viral blood specimen clearance, Effect on hemostasis disorders, Kinetics of appearance of neutralizing antibodies, Transfusion endotheliopathy effect, Transfusion biological Inflammation effect, Transfusion hemovigilance, Decrease in the consumption of antibiotics
|
NCT04395170
|
Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19. |
Not yet recruiting |
Phase 2|Phase 3 |
Sep/01/2020 |
Jun/01/2021 |
- Alternative id -
LFCOLCOVID-19-001
- Interventions -
Biological: COVID-19 convalescent plasma, Biological: Anti-COVID-19 human immunoglobulin, Drug: Standard (specific) therapy for COVID-19
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
LifeFactors Zona Franca SAS, Medellín, Antioquia, Colombia
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
75
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Admission to ICU and/or mechanical ventilation, Length of hospital stay, Neutralizing antibody (IgG) titers against COVID-19, Safety - Adverse events, Death
|
NCT04558476
|
Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation |
Recruiting |
Phase 2 |
Sep/01/2020 |
Sep/01/2022 |
- Acronym - CONFIDENT
- Alternative id -
2020-003102-31
- Interventions -
Biological: Convalescent Plasma, Other: Standard of Care
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Clinique Saint Pierre Ottignies, Ottignies, Brabant Wallon, Belgium; Centre Hospitalier Wallonie Picarde, Tournai, Hainaut, Belgium; OLVZ Aalst, Aalst, Belgium; UZ Antwerpen, Antwerp, Belgium; Imelda ZH Bonheiden, Bonheiden, Belgium; AZ Sint-Jan Brugge, Bruges, Belgium; CHU Saint Pierre, Brussels, Belgium; Erasme, Brussels, Belgium; UZ Brussel, Brussel, Belgium; CHU Charleroi Marie Curie, Charleroi, Belgium; AZ Sint Blasius, Dendermonde, Belgium; UZ Gent, Gent, Belgium; AZ Groeningen Kortrijck, Kortrijk, Belgium; CHR Citadelle, Liège, Belgium; CHU Liège, Liège, Belgium; UC Louvain, Louvain, Belgium; AZ Delta, Roeselare, Belgium; CHU UCL Namur-Godinne, Yvoir, Belgium
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
500
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Vital status, day 90 mortality, number of ventilator-free days at day 28, number of renal replacement therapy free days at day 28, number of vasopressors free-days at day 28, use of ECMO before day 28, value of the SOFA score at days 7, 14 and 28, changes in SOFA scores (delta SOFA) over 7, 14 and 28 days, assessment of the SARS-CoV-2 viral load, blood C reactive protein (CRP) concentration, ferritin concentration, lymphocyte count, length of stay in the acute care hospital, location of the patient, Katz Index of independence in Activity Day Living functional score, Hospital Anxiety and Depression Scale (HADS), Quality of life scale EQ-5D-5L, Transfusion related adverse events
|
NCT04433910
|
A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19 |
Completed |
Phase 2 |
Aug/30/2020 |
Feb/22/2021 |
- Acronym - CAPSID
- Alternative id -
CAPSID2020-DRK-BSD, 2020-001310-38
- Interventions -
Drug: Convalesscent Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
University Hospital Ulm, Ulm, Baden-Württmberg, Germany; University Hopsital Frankfurt, Frankfurt, Hessia, Germany; Saarland University Hospital, Homburg, Saarland, Germany; University Hospital Berlin, Charite, Berlin, Germany; Universitiy Hospital Dresden, Dresden, Germany; University Düsseldorf, Düsseldorf, Germany; University Hospital Freiburg, Freiburg, Germany; University Hospital Gießen, Gießen, Germany; University Hopsital Greifswald, Greifswald, Germany; Städtisches Klinikum Karslruhe, Karlsruhe, Germany; Universtity Hospital Schleswig-Holstein, Kiel, Germany; Universtity Hospital Schleswig-Holstein, Lübeck, Germany; University Hospital Mannheim, Mannheim, Germany; University Hospital Marburg, Marburg, Germany; Klinikum Stuttgart, Stuttgart, Germany; University Hospital Tübingen, Tübingen, Germany
- Study designs -
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
106
- Age -
18 Years to 75 Years (Adult, Older Adult)
- Outcome measures -
Composite endpoint of survival and no longer fulfilling criteria of severe COVID-19., Time to clinical improvement, Frequency and severity of adverse events by CTCAE v5.0, (Key secondary endpoint), Case fatality rate, Length of hospital stay Length of hospital stay (if applicable), Length of stay in ICU, Duration of ventilation support / ECMO, Time until negative SARS-CoV-2 PCR (nasopharyngeal sample), Predictive value of comorbidities, Predictive value of coagulation markers, Predictive value of inflamation, Percentage of former COVID-19 patients willing to donate qualifying for plasma donation., Amount of Plasma Units that could be collected for the clinical trial, Titer of anti-SARS-CoV-2 in transfused plasma units, Impact of donor characteristics on anti-SARS-CoV-2 humoral response, Course of anti-SARS-CoV-2 titer in both patient groups at different time points related to transfusion of convalescent plasma, Correlation of anti-SARS-CoV-2 titer in transfused plasma units and primary and key secondary outcomes., Effect of timing of plasma transfusions
|
NCT04388410
|
Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19 |
Recruiting |
Phase 2|Phase 3 |
Aug/25/2020 |
Dec/31/2020 |
- Acronym - EPCOvid-1
- Alternative id -
3380
- Interventions -
Biological: convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Tlalpan, Mexico
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor), Primary Purpose: Treatment
- Enrollment -
410
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Severity and death, Adverse events that require study treatment interruption, Time to clinical improvement, Antibodies against SARS-CoV-2, Disease progression 1, Disease progression 2, Time on mechanical ventilation, Number of days with fever, Adverse events attributed to the study intervention
|
NCT04513158
|
Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection |
Recruiting |
Phase 2 |
Aug/14/2020 |
Dec/31/2021 |
- Alternative id -
20-N0124
- Interventions -
Biological: Convalescent Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Norton Hospital, Louisville, Kentucky, United States; Norton Women's and Children's Hospital, Louisville, Kentucky, United States; Norton Audubon Hospital, Louisville, Kentucky, United States; Norton Brownsboro Hospital, Louisville, Kentucky, United States
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
100
- Age -
18 Years to 99 Years (Adult, Older Adult)
- Outcome measures -
Determine the therapeutic efficacy (response rate) of convalescent plasma infusion in patients at high risk for mortality when infected by SARS-CoV-2 (COVID-19)., Determine the immunologic effects of convalescent plasma infusion, Absolute lymphocyte count (10*3/uL), reatinine kinase (mg/dL), C-reactive protein (mg/dl), D-Dimer (ng/ml FEU), Interleukin-6 (pg/ml), Ferritin (ng/mL)
|
NCT04438057
|
Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19 |
Recruiting |
Phase 2 |
Aug/12/2020 |
Aug/12/2021 |
- Alternative id -
MIDC-CCP
- Interventions -
Biological: CCP
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Metro Infectious Disease Consultants, Burr Ridge, Illinois, United States
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
150
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Time to Resolution of Symptoms, SAEs within 24 hours of plasma infusion, Decrease in Inflammatory Markers, Hospitalization within 28 days
|
NCT04355767
|
Convalescent Plasma in Outpatients With COVID-19 |
Completed |
Phase 3 |
Aug/11/2020 |
Mar/29/2021 |
- Acronym - C3PO
- Alternative id -
C3PO, 1OT2HL156812-01
- Interventions -
Biological: Convalescent Plasma, Biological: Saline
- Study type - Interventional
- Study results -
Has Results
- Study locations -
Chandler Regional Medical Center, Chandler, Arizona, United States; Valleywise Health Medical Center, Phoenix, Arizona, United States; UCSD Health La Jolla, La Jolla, California, United States; Loma Linda University Medical Center, Loma Linda, California, United States; Ronald Reagan UCLA Medical Center, Los Angeles, California, United States; Cedars-Sinai Medical Center, Los Angeles, California, United States; UC Davis Medical Center, Sacramento, California, United States; Stanford University, Stanford, California, United States; Harbor-UCLA Medical Center, Torrance, California, United States; University of Colorado Hospital, Aurora, Colorado, United States; UF Health Shands Hospital, Gainesville, Florida, United States; Jackson Memorial Hospital, Miami, Florida, United States; Grady Memorial Hospital, Atlanta, Georgia, United States; Rush University Medical Center, Chicago, Illinois, United States; University of Illinois Hospital, Chicago, Illinois, United States; University of Chicago Medical Center, Chicago, Illinois, United States; University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States; University of Louisville Hospital, Louisville, Kentucky, United States; Maine Medical Center, Portland, Maine, United States; Tufts Medical Center, Boston, Massachusetts, United States; Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States; Newton-Wellesley Hospital, Newton, Massachusetts, United States; Baystate Medical Center, Springfield, Massachusetts, United States; University of Michigan University Hospital, Ann Arbor, Michigan, United States; Detroit Receiving Hospital, Detroit, Michigan, United States; Harper University Hospital, Detroit, Michigan, United States; Henry Ford Hospital, Detroit, Michigan, United States; Sinai-Grace Hospital, Detroit, Michigan, United States; Spectrum Health Hospitals Butterworth Hospital, Grand Rapids, Michigan, United States; William Beaumont Hospital, Royal Oak, Michigan, United States; William Beaumont Hospital-Troy, Troy, Michigan, United States; HealthPartners Methodist Hospital, Saint Louis Park, Minnesota, United States; Regions Hospital, Saint Paul, Minnesota, United States; Barnes Jewish Hospital, Saint Louis, Missouri, United States; Cooper University Hospital, Camden, New Jersey, United States; Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States; University of New Mexico Hospital, Albuquerque, New Mexico, United States; SUNY Downstate Medical Center, Brooklyn, New York, United States; Duke University Hospital, Durham, North Carolina, United States; Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States; University of Cincinnati Medical Center, Cincinnati, Ohio, United States; OSU Wexner Medical Center, Columbus, Ohio, United States; Mercy St. Vincent Medical Center, Toledo, Ohio, United States; Oregon Health & Science University Hospital, Portland, Oregon, United States; Geisinger Medical Center, Danville, Pennsylvania, United States; Temple University Hospital, Philadelphia, Pennsylvania, United States; Einstein Medical Center, Philadelphia, Pennsylvania, United States; UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States; William P. Clements Jr. University Hospital, Dallas, Texas, United States; Ben Taub General Hospital, Houston, Texas, United States; Memorial Hermann Texas Medical Center, Houston, Texas, United States; University of Utah Healthcare, Salt Lake City, Utah, United States; Froedtert Hospital, Milwaukee, Wisconsin, United States
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double (Participant, Outcomes Assessor), Primary Purpose: Treatment
- Enrollment -
511
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Number of Patients With Disease Progression (Intention-to-treat Population), Number of Patients With Disease Progression (Per-protocol Population), Worst Severity Rating on the WHO COVID Ordinal Scale for Clinical Improvement During the 30 Days Following Randomization, Number of Patients With Worsening of Symptoms at Day 15 as a Measure of Time to Disease Progression, Number of Hospital-free Days During the 30 Days Following Randomization, All-cause Mortality
|
NCT04747158
|
COVID-19 Convalescent Plasma Therapy |
Completed |
Phase 2|Phase 3 |
Aug/10/2020 |
Jan/10/2021 |
- Acronym - TPCC
- Alternative id -
PINV20-388
- Interventions -
Biological: Convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Facultad de Ciencias Médicas - Universidad Nacional de Asunción, Asunción, Paraguay
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
350
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Overall survival (30-day mortality), Median length of hospital stay, Change in clinical status, Change in inflammatory marker: ferritin, Change in inflammatory marker: D dimer, Change in inflammatory marker: leukocytes, Serum Antibody Titers, Transfer to ICU, Transfusion related events
|
NCT04332835
|
Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study |
Completed |
Phase 2|Phase 3 |
Aug/08/2020 |
Nov/15/2020 |
- Acronym - CP-COVID-19
- Alternative id -
ABN011-2
- Interventions -
Drug: Plasma, Drug: Standard Therapy
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Universidad del Rosario, Bogota, Cundinamarca, Colombia
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single (Outcomes Assessor), Primary Purpose: Treatment
- Enrollment -
92
- Age -
18 Years to 100 Years (Adult, Older Adult)
- Outcome measures -
Change in Viral Load, Change in Immunoglobulin G COVID-19 Titers, Intensive Care Unit Admission, Length of Intensive Care Unit stay, Length of hospital stay (days), Requirement of mechanical ventilation, Duration (days) of mechanical ventilation, Clinical status assessed according to the World Health Organization guideline, Mortality
|
NCT04432103
|
Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma |
Terminated |
Phase 3 |
Aug/08/2020 |
Jan/29/2021 |
- Alternative id -
ABC-20-14
- Interventions -
Biological: Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients, Biological: Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Centro Medico Abc, Mexico City, Mexico
- Study designs -
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
6
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
INCIDENCE OF CRITICAL PNEUMONIA, MORTALITY RATE AMONG CRITICAL PNEUMONIA PATIENTS, INCIDENCE OF MECHANICAL VENTILATION, DAYS OF MECHANICAL VENTILATION
|
NCT04480632
|
Therapeutic Plasmapheresis in Critically Ill Adult Patients With COVID-19 Confirmed Diagnosis |
Not yet recruiting |
Phase 2 |
Aug/01/2020 |
Aug/01/2022 |
- Acronym - PLASMA
- Alternative id -
CEI-2020-01200
- Interventions -
Biological: Convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Hospital Internacional de Colombia, Piedecuesta, Santander, Colombia
- Study designs -
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
44
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
In-hospital mortality, Incidence of renal replacement therapy, Incidece of adverse events
|
NCT04516954
|
Convalescent Plasma for COVID-19 Patients |
Enrolling by invitation |
Early Phase 1 |
Aug/01/2020 |
Dec/30/2020 |
- Acronym - CPCP
- Alternative id -
ISC.20.11.1
- Interventions -
Biological: Convalescent COVID 19 Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Vinmec Research Institute of Stem cell and Gene Technology, Hanoi, Vietnam
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
10
- Age -
18 Years to 75 Years (Adult, Older Adult)
- Outcome measures -
Evaluate the safety, Change in requirement for mechanical ventilatory support
|
NCT04462848
|
Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions |
Not yet recruiting |
Phase 1 |
Aug/01/2020 |
Dec/01/2024 |
- Alternative id -
IRB#20-001263
- Interventions -
Biological: anti-SARS-CoV-2 human convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
University of California, Los Angeles (UCLA), Los Angeles, California, United States
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
30
- Age -
1 Month to 17 Years (Child)
- Outcome measures -
Cumulative incidence of Grade 3 and Grade 4 adverse events, Cumulative incidence of serious adverse events, Proportion of participants with disease worsening event., Serum concentration at baseline, Day 7, Day 14, and Day 28 for anti-SARS-CoV-2 antibodies, Percentage of participants with a natural antibody response to SARS-CoV-2 infection
|
NCT04570982
|
Clinical Protocol for Convalescent Plasma and Remdesivir Therapy in Nepal |
Recruiting |
|
Jul/30/2020 |
Dec/30/2020 |
- Acronym - CPT-R-Nepal
- Alternative id -
NHRC2020-001
- Interventions -
Biological: Convalescent Plasma
- Study type - Observational
- Study results -
No Results Available
- Study locations -
Narayani Hospital, Birgunj, Nepal; Seti Provincial Hospital, Dhangadi, Nepal; BP Koirala Institute of Health Sciences (BPKIHS), Dharān Bāzār, Nepal; Sukraraj Tropical Disease Hospital, Kathmandu, Nepal; TU Teaching Hospital, Kathmandu, Nepal; Bheri Provincial Hospital, Nepalgunj, Nepal
- Study designs -
Observational Model: Case-Crossover, Time Perspective: Prospective
- Enrollment -
200
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Availability of convalescent plasma, Amount of Plasma, Demographics of recipients, Co-morbidity of recipient, Donor status, Adverse events of convalescent COVID-19 plasma and Remdesivir Therapy, Hospital and ICU length of stay, Disposition of patients including survival
|
NCT04973488
|
Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients |
Completed |
Phase 2|Phase 3 |
Jul/25/2020 |
Jan/10/2021 |
- Alternative id -
STUDYTPECVP20
- Interventions -
Other: Therapeutic plasma exchange
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Municipal Hospital "Dr. Teodor Andrei" Lugoj, Lugoj, Timis, Romania
- Study designs -
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
38
- Age -
18 Years to 90 Years (Adult, Older Adult)
- Outcome measures -
Survival, Partial pressure of arterial oxygen (PaO2) to fractional inspired oxygen (FiO2) ratio (P/F ratio), C reactive protein (CRP), Lactate dehydrogenase (LDH), Ferritin
|
NCT04460547
|
Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic |
Not yet recruiting |
|
Jul/25/2020 |
Sep/20/2020 |
- Alternative id -
COAHS
- Interventions -
Drug: Convalescent Plasma Transfusion, Drug: Hydroxychloroquine, Drug: DAS181, Drug: Ivermectin, Drug: Interferon Beta-1A
- Study type - Observational
- Study results -
No Results Available
- Study designs -
Observational Model: Cohort, Time Perspective: Retrospective
- Enrollment -
200
- Age -
1 Year and older (Child, Adult, Older Adult)
- Outcome measures -
Geographical distribution of the interventional studies after 11th of March 2020., Geographical distribution of the Observational studies after 11th of March 2020., Monthly Research study completion rate as per geographic distribution of the Research., Statistical correlation of the interventional studies Research with developed, developing and under developed countries., Statistical correlation of the observational studies Research with developed, developing and under developed countries., Statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries., Statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries., Statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries.
|
NCT04365439
|
Convalescent Plasma for COVID-19 |
Active, not recruiting |
Not Applicable |
Jul/20/2020 |
Jun/30/2021 |
- Alternative id -
2020-00895
- Interventions -
Biological: Blood plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Ospedale Regionale Locarno, Locarno, Ticino, Switzerland
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
11
- Age -
18 Years to 75 Years (Adult, Older Adult)
- Outcome measures -
Titers of anti-SARS-CoV-2 antibodies in the plasma derived from convalescent donors, Change in titers of anti-SARS-CoV-2 antibodies in patients' plasma, Change in inflammatory cytokines concentration (e.g. IL-6, HMGB1), Viral load decay in the recipient after plasma transfusion with semiquantitative assessment of nasopharyngeal swabs, Number of patients with improvement in the 7-points Ordinal Scale, Proportion of patients with adverse events, severity of adverse events
|
NCT04432272
|
ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS) |
Terminated |
Phase 2 |
Jul/16/2020 |
Nov/28/2020 |
- Acronym - ABACCuS
- Alternative id -
2020-198
- Interventions -
Biological: COVID-19 convalescent plasma
- Study type - Interventional
- Study results -
Has Results
- Study locations -
William Beaumont Hospital, Royal Oak, Michigan, United States
- Study designs -
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
71
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Avoidance of Intubation at 28 Days (Group A), Mortality (Group B), Cardio-circulatory Arrest, Patient Outcome at 28 Days, Renal Failure, Liver Failure, Cytokine Storm, Respiratory Support, Vasopressor Medication Support, Length of ICU Length of Stay, Intensive Care Unit (ICU) Mortality, Hospital Length of Stay, Ventilator Free Days, Intubation Duration, Readmission, Serum Anti-SARS-CoV-2 IgG, SARS-CoV-2 RNA, Mortality (Group A), Time From Transfusion to End of Ventilator Support (Group B)
|
NCT04716556
|
TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa in COVID-19 Patients |
Completed |
Not Applicable |
Jul/16/2020 |
May/31/2021 |
- Alternative id -
TSUNAMI
- Interventions -
Biological: Convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
SOD Clinica Malattie Infettive Tropicali, Parassitologia, Epatiti Croniche - AOU Ospedali Riuniti di Ancona, Ancona, Italy; Ospedale di Arezzo, Arezzo, Italy; Clinica Malattie Infettive, Università degli Studi di Bari, Bari, Italy; Ospedale Papa Giovanni XXIII-Dip. emergenza, Urgenza e area critica, Bergamo, Italy; UOC Malattie Infettive - AOU Bologna, Bologna, Italy; UO PID Tossicologia Applicata - Dip. Scienze Biomediche e Biotecnologiche - Università di Catania - AOU Policlinico Vittorio Emanuele, Catania, Italy; Ospedale Città di Castello, Città Di Castello, Italy; Ospedale di Empoli, Empoli, Italy; UOC Malattie Infettive - ASUR Marche Area Vasta 4, Fermo, Italy; UOC Malattie Infettive - AOU Ferrara, Ferrara, Italy; Ospedale Santa Maria Annunziata, Firenze, Italy; SOD Malattie Infettive e Tropicali - AOU Careggi, Firenze, Italy; Dip.Medicina Clinica e Sperimentale - Policlinico "Riuniti" di Foggia, Foggia, Italy; Nuovo Ospedale S. Giovanni Battista Usl Umbria2, Foligno, Italy; U.O.C. Malattie Infettive ASL Frosinone, Frosinone, Italy; U.O. Malattie Infettive IRCCS-Ospedale Policlinico San Martino, Genova, Italy; Ospedale di Grosseto, Grosseto, Italy; ASL 5 Spezzina - SC Malattie Infettive, La Spezia, Italy; ASST Lecco - Malattie Infettive, Lecco, Italy; Ospedale di Livorno, Livorno, Italy; Ospedale di Lucca, Lucca, Italy; S.C. Pneumologia e Utir ASST Mantova - Ospedale Carlo Poma, Mantova, Italy; Ospedale Dell'Angelo - UOC Malattie Infettive, Mestre, Italy; ASST Santi Paolo e Carlo, Milano, Italy; Ospedale Luigi Sacco, Milano, Italy; SC Malattie Infettive ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy; Ospedale San Gerardo, Monza, Italy; Malattie Infettive - AOU Federico II di Napoli, Napoli, Italy; UOC Malattie Infettive ad indirizzo Respiratorio - PO Cotugno - AORN "Dei Colli", Napoli, Italy; UOC Malattie Infettive e Tropicali - AOU Policlinico, Palermo, Italy; Dip. Medicina Diagnost. e Servizi Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Azienda Ospedaliero-Universitaria di Perugia, Perugia, Italy; UOC Malattie Infettive - Azienda Ospedali Riuniti Marche Nord, Pesaro, Italy; AOU Pisana, Pisa, Italy; Ospedale Pistoia, Pistoia, Italy; Ospedale Prato, Prato, Italy; Malattie Infettive Ravenna, Ravenna, Italy; UOC Malattie Infettive - AUSL Reggio Emilia, Reggio Emilia, Italy; Malattie Infettive - Rimini Forlì Cesena, Rimini, Italy; Campus Bio Medico - UO Anestesia e Rianimazione, Roma, Italy; ASL 1 Imperiese - SC Malattie Infettive, Sanremo, Italy; ASL 2 Savonese - SC Malattie Infettive, Savona, Italy; Ospedale di Siena, Siena, Italy; Ospedale di Sondrio - dipartimento di Medicina, Sondrio, Italy; AOU di Terni, Terni, Italy; Ospedale Ca Foncello - UOC Malattie Infettive, Treviso, Italy; A.O. Integrata Università di Verona, Verona, Italy; Ospedale Viareggio, Viareggio, Italy
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
474
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Number of patients who meet invasive mechanical ventilation or death, Mortality rates, Time to invasive mechanical ventilation or death, Time to virologic recover, Hospitalization time, Adverse events
|
NCT04547660
|
Convalescent Plasma for Severe COVID-19 Patients |
Completed |
Phase 3 |
Jul/16/2020 |
Jan/07/2021 |
- Acronym - PLACOVID
- Alternative id -
2020-0158
- Interventions -
Biological: Convalescent Plasma, Other: Best Supportive Care
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single (Outcomes Assessor), Primary Purpose: Treatment
- Enrollment -
160
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Clinical improvement, 6-point ordinal scale proportion at 14 days, 6-point ordinal scale proportion at 28 days, Overall mortality, Days alive and free of respiratory support (DAFOR28), Mechanical ventilation, PaO2/FiO2 ratio, Hospital stay, Lactate Dehydrogenase, Troponin I, C Reactive Protein, D-Dimers, Fibrinogen, Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT), Tumor Necrosis Factor Alfa (TNF-Alfa), Interleukin-6 (IL-6), RT-PCR, Sequential Organ Failure Assessment (SOFA) score, National Early Warning Score 2 (NEWS) 2, Safety and Adverse Events
|
NCT04408040
|
Use of Convalescent Plasma for COVID-19 |
Terminated |
Phase 2 |
Jul/14/2020 |
Sep/14/2021 |
- Alternative id -
NSH 1281
- Interventions -
Biological: Convalescent Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Northside Hospital, Atlanta, Georgia, United States
- Study designs -
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
7
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Arms 1 & 2: number of critical and severe COVID-19 infected patients who are transfused with convalescent plasma result in lower death rates than the reported fatality rate, Arms 1 & 2: number of critical and severe COVID-19 infected patients who survive the infection, Arm 3: number of high risk COVID-19 infected patients who are transfused with convalescent plasma result in lower incidence of progression to severe or critical disease than the reported case rate, Arm 4: number of health care providers who are at risk to exposure to COVID-19 who are transfused with convalescent plasma result in lower incidence of developing COVID-19 infection than the reported case rate
|
NCT04497779
|
Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma |
Recruiting |
|
Jul/13/2020 |
Aug/21/2023 |
- Alternative id -
20204, NCI-2020-04000, P30CA033572, TGen
- Interventions -
Procedure: Biospecimen Collection, Other: Diagnostic Laboratory Biomarker Analysis, Other: Electronic Health Record Review, Other: Questionnaire Administration
- Study type - Observational
- Study results -
No Results Available
- Study locations -
City of Hope Medical Center, Duarte, California, United States
- Study designs -
Observational Model: Cohort, Time Perspective: Prospective
- Enrollment -
800
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Convalescent plasma (CCP) units infused in coronavirus disease-2019 (COVID-19) patients, All-cause mortality, Donor antibody levels, Incidence of adverse events, CCP recipient outcomes
|
NCT04803370
|
Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma |
Recruiting |
Not Applicable |
Jul/08/2020 |
Sep/01/2021 |
- Alternative id -
CO-PLASMA-2020
- Interventions -
Other: Convalescent Plasma with antibody against SARS-CoV-2., Other: Standard treatment for COVID-19
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
University Hospital Son Llatzer, Palma De Mallorca, Islas De Balears, Spain
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
100
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
WHO clinical progression scale, lung X-ray, Concomitant medication assessment, Hematimetry, Activated partial thromboplastin time, Fibrinogen level, Fragment D-dimer assessment, Glomerular Filtration Rate assessment, Ferritin blood assessment, C-reactive protein assessment, Lactate Dehydrogenase (LDH) assessment, Troponin I assessment, Procalcitonin assessment, Interleukin-6 assessment, partial pressure of oxygen (pO2) assessment, Quantitative determination of antibodies, SARS-Cov-2 viral quantification in a nasopharyngeal specimen, Time to negativization of RT-PCR, Pneumonia Severity Index (PSI) score, Percentage of patients requiring admission to intensive care units., Mortality rate at 15 days, Mortality rate at 30 days, Length of stay
|
NCT04452812
|
Statistical and Epidemiological Study Based on the Use of Convalescent Plasma for the Management of Patients With COVID-19 |
Not yet recruiting |
Phase 1|Phase 2 |
Jul/06/2020 |
Apr/01/2021 |
- Acronym - PROMETEO
- Alternative id -
HUS-001/2020
- Interventions -
Biological: Convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Hospital Universitario "Dr. Gonzalo Valdés Valdés", Saltillo, Coahuila, Mexico
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double (Participant, Care Provider), Primary Purpose: Treatment
- Enrollment -
15
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
All-cause mortality, Side effects, Length of stay in Intensive Care Unit (ICU), Length of stay in hospitalization, Days of mechanical ventilation, Inflammatory biomarkers (d-dimer), Inflammatory biomarkers (c-reactive protein), Inflammatory biomarkers (lactate dehydrogenase), Inflammatory biomarkers (ferritin)
|
NCT04463823
|
"NORPLASMA" Covid-19 Convalescent Plasma Treatment Monitoring Study |
Recruiting |
|
Jul/06/2020 |
May/31/2025 |
- Acronym - MONITOR
- Alternative id -
148622
- Study type - Observational
- Study results -
No Results Available
- Study locations -
Helse Fonna, Haugesund, Norway; Sorlandet hospital, Kristiansand, Norway; Akershus University Hospital, Lørenskog, Norway; Oslo University Hospital, Oslo, Norway; Sykehuset Ostfold, Sarpsborg, Norway; Sykehuset Telemark, Skien, Norway; St.Olavs Hospital, Trondheim, Norway
- Study designs -
Observational Model: Case-Only, Time Perspective: Prospective
- Enrollment -
500
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
observation
|
NCT04458363
|
Convalescent Plasma in Pediatric COVID-19 |
Completed |
Early Phase 1 |
Jul/04/2020 |
Sep/01/2020 |
- Alternative id -
STUDY00000789
- Interventions -
Biological: Convalescent Plasma (CP), Drug: Standard COVID-19 therapies
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
3
- Age -
up to 22 Years (Child, Adult)
- Outcome measures -
Number of grade 3-5 adverse events that are possible, probably or definitely related to the convalescent plasma (CP) infusion, Change in percent of supplemental oxygen, Number of patients that required change in level of respiratory support, Mortality, Mean length of ICU stay (days), Mean length of hospital stay (days), Mean length of ventilation (days), Number of patients with progression to renal dysfunction and/or multisystem organ failure, IL-6 level, Number of anti-SARS CoV 2 specific T cells, Diversity of circulating T cells, ARS-CoV-2 Antibody Titer, SARS-CoV-2 Neutralizing Titer
|
NCT04425837
|
Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19 |
Not yet recruiting |
Phase 2|Phase 3 |
Jul/01/2020 |
Feb/01/2021 |
- Alternative id -
PLASMA COVID-19
- Interventions -
Biological: SARS-CoV-2 convalescent plasma treatment, Other: Standard care
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Fundación Santa Fe de Bogotá, Bogotá, Cundinamarca, Colombia
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single (Outcomes Assessor), Primary Purpose: Treatment
- Enrollment -
236
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Mortality, Adverse events, ICU admission, Mechanical ventilation, ICU length, Reduction of D Dimer, LDH reduction, Reduction of Troponin level, Decrease in ferritin level, Decrease in procalcitonin level, Decrease in CRP, Increase in lymphocyte count, Increase in PaO2 / Fio2, Decrease in Sequential Organ failure assessment (SOFA ) score, Extracorporeal membrane oxygenation (ECMO), Lung infiltration
|
NCT04555109
|
Convalescent Plasma for COVID-19 Research Donor Study |
Active, not recruiting |
|
Jun/30/2020 |
Oct/31/2022 |
- Acronym - CONCOR-Donor
- Alternative id -
1000070462
- Study type - Observational
- Study results -
No Results Available
- Study locations -
The Hospital for Sick Children, Toronto, Ontario, Canada
- Study designs -
Observational Model: Cohort, Time Perspective: Prospective
- Enrollment -
1000
- Age -
17 Years to 85 Years (Child, Adult, Older Adult)
- Outcome measures -
Seroprevalence and duration of protective immunity
|
NCT04353206
|
Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure |
Terminated |
Early Phase 1 |
Jun/27/2020 |
Nov/01/2020 |
- Alternative id -
Acute Care CP Consortium Trial
- Interventions -
Biological: Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
8700 Beverly Blvd., Los Angeles, California, United States; Johns Hopkins University, Baltimore, Maryland, United States
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
6
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Proportion of subjects who consent to the study and receive at least one dose of convalescent plasma., Overall survival of patients in the ICU receiving at least once dose of convalescent plasma for Covid-19-induced respiratory failure.
|
NCT04468009
|
Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma |
Completed |
Phase 2 |
Jun/25/2020 |
Jun/19/2021 |
- Alternative id -
1725
- Interventions -
Biological: Convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Hospital Francisco Javier Muñiz, Ciudad Autonoma de Buenos Aire, Argentina
- Study designs -
Allocation: Randomized, Intervention Model: Sequential Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
134
- Age -
18 Years to 100 Years (Adult, Older Adult)
- Outcome measures -
Mortality at ICU at 30 days, Mortality at ICU at 90 days, SOFA score of study days 1, 3, 5, 7, 14 and 28, Need for supportive therapy after enrollment, Lenght of stay in ICU, Lenght of mechanical ventilation, Lenght of hospitalization
|
NCT04418518
|
A Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness |
Recruiting |
Phase 3 |
Jun/24/2020 |
Dec/01/2021 |
- Acronym - CONCOR-1
- Alternative id -
20-04021981
- Interventions -
Biological: Convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Brooklyn Methodist Hospital, Brooklyn, New York, United States; Weill Cornell Medicine, New York, New York, United States; Lower Manhattan Hospital, New York, New York, United States
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
1200
- Age -
18 Years to 70 Years (Adult, Older Adult)
- Outcome measures -
Intubation or death in hospital, Need for Intubation, Time to intubation, Ventilator-free days, In-hospital death, Time to in-hospital death, Death at 30 days, Length of stay in intensive care unit (ICU), Length of stay in hospital, Need for extracorpeal membrane oxygenation (ECMO), Need for renal replacement therapy, Development of myocarditis, Adverse events and serious adverse events, CCP transfusion-associated adverse events (AE)
|
NCT04542967
|
Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease |
Completed |
Phase 2 |
Jun/23/2020 |
Sep/30/2020 |
- Acronym - PC-COVID-HCM
- Alternative id -
047/2020
- Interventions -
Biological: Biological
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Hospital Central Militar, Mexico City, Mexico
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor), Primary Purpose: Treatment
- Enrollment -
150
- Age -
18 Years to 90 Years (Adult, Older Adult)
- Outcome measures -
Disease progression, Side effects, Mortality, Respiratory improvement, Clinical improvement, Acute adverse events (AAE)
|
NCT04385186
|
Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19 |
Not yet recruiting |
Phase 2 |
Jun/20/2020 |
Dec/30/2020 |
- Alternative id -
CT01
- Interventions -
Drug: Inactivated convalescent plasma, Drug: Support treatment
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Clínica Antioquía, Medellín, Antioquía, Colombia; Clínica Sagrado Corazón, Medellín, Antioquía, Colombia; IPS Universitaria, Medellín, Antioquía, Colombia; Universidad de Antioquía, Medellín, Antioquía, Colombia; National Blood Center Foundation, Hemolife/Fundación Banco Nacional de Sangre Hemolife, Bogotá, Cundinamarca, Colombia; Clínica Rosales, Pereira, Risaralda, Colombia; Clinica Nuestra, Cali, Valle, Colombia; Clínica Corpas, Bogotá, Colombia; E.S.E Hospital San Rafael Facatativa, Facatativa, Colombia; Clínica la Estancia, Popayán, Colombia
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single (Investigator), Primary Purpose: Treatment
- Enrollment -
60
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Mortality reduction in CoViD-19 patients treated with inactivated convalescent plasma + support treatment, Clinical evolution, Clinical evolution by seven-parameter ordinal scale, Multi-organ failure progression, Change in hemoglobin concentration, Change in blood cell count, Change in serum creatinine level, Change in aspartate aminotransferase level, Change in alanin aminotransferase level, Change in bilirubin level, Change in lactate dehydrogenase level, Change in creatine kinase level, Change in creatine kinase MB level, Change in C reactive protein concentration, Change in D Dimer concentration, Change in Procalcitonin concentration, Change in IL6 level, Radiography imaging, Tomography imaging, Assessment of oxygenation, Viral Load, Antibody titer, Oxygen-free days through Day 60, Mechanical ventilation-free days through Day 28, Intensive Care Unit (ICU)-free days through Day 28, Hospital-free days through Day 60
|
NCT04542941
|
Assessment of Safety and Efficacy of CCP |
Completed |
Not Applicable |
Jun/16/2020 |
Dec/31/2020 |
- Acronym - COVIDIT
- Alternative id -
CCP
- Interventions -
Biological: COVID Convalescent Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Mulago Specialised Hospital, Kampala, Uganda
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
136
- Age -
18 Years to 100 Years (Adult, Older Adult)
- Outcome measures -
Time to viral clearance (RT-PCR negativity), Time to symptom resolution, Time to severe/critical disease, Number of participants reporting an adverse event as evidenced by clinical manifestations
|
NCT04428021
|
Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure |
Completed |
Phase 2 |
Jun/15/2020 |
Oct/31/2021 |
- Acronym - PLACO-COVID
- Alternative id -
CS3/33
- Interventions -
Drug: Standard Therapy Protocol (STP), Other: STP + Standard Plasma (SP), Other: STP + COVID-19 Convalescent Plasma (CP)
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
AO Città della salute e della scienza di Torino, Torino, Italy
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Triple (Participant, Care Provider, Outcomes Assessor), Primary Purpose: Treatment
- Enrollment -
180
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
30-days survival, Ventilator free survival, 6-months survival, Incidence of complications, Days in intensive care units (ICU), Positivity for Immunoglobulin G to SARS-Cov-2, Clearance of viral load, Sequential Organ Failure Assessment (SOFA) score, Any variation from Standard Therapy Protocol
|
NCT04425915
|
Efficacy of Convalescent Plasma Therapy in Patients With COVID-19 |
Completed |
Phase 3 |
Jun/14/2020 |
Dec/15/2020 |
- Alternative id -
ILBS-COVID-04
- Interventions -
Biological: Convalescent Plasma, Other: Standard of Care
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Maulana Azad Medical College, New Delhi, Delhi, India; Institute of Liver & Biliary Sciences, New Delhi, Delhi, India; Rajiv Gandhi Super Speciality Hospital, New Delhi, Delhi, India
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
400
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Efficacy of convalescent plasma in severe COVID 19 patients in time to clinical improvement (Clinical improvement: Reduction of two points in ordinal scale or live discharge from the intensive care unit, whichever is earlier), Proportion of patients in each category according to the ordinal scale, Duration of oxygen therapy in both groups, Duration of hospital stay in both groups, Proportion of patients on mechanical ventilation at day 7 in both groups, Mortality in both groups, Duration of Intensive Care Unit stay, Incidence of adverse effects in both groups, Presence of antibodies against SARS-CoV-2 in serum after plasma administration, Change in Cytokines in both groups, Change in acute phase reactants in both groups, Correlation of the titers in COVID-19 convalescent plasma donors with duration of illness, the severity of symptoms, duration of hospital stay, drugs used in therapy, duration between recovery, and donation.
|
NCT04323800
|
Convalescent Plasma to Stem Coronavirus (CSSC-001) |
Completed |
Phase 2 |
Jun/10/2020 |
Jun/22/2021 |
- Acronym - CSSC-001
- Alternative id -
IRB00245634
- Interventions -
Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
University of Alabama at Birmingham, Birmingham, Alabama, United States; Center for American Indian Health - Whiteriver Office, Whiteriver, Arizona, United States; University of California, San Diego, La Jolla, California, United States; University of California, Los Angeles, Los Angeles, California, United States; University of California, Irvine Health, Orange, California, United States; Western Connecticut Health Network, Danbury Hospital, Danbury, Connecticut, United States; Western Connecticut Health Netowrk, Norwalk Hospital, Norwalk, Connecticut, United States; MedStar Georgetown University Hospital, Washington, District of Columbia, United States; University of Miami, Coral Gables, Florida, United States; University of Miami Clinical Translational Research Site, Miami, Florida, United States; NorthShore University HealthSystem, Evanston, Illinois, United States; Anne Arundel Medical Center, Annapolis, Maryland, United States; The Johns Hopkins University, Baltimore, Maryland, United States; University of Massachusetts Worcester, Worcester, Massachusetts, United States; Wayne State University, Detroit, Michigan, United States; University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States; Center for American Indian Health - Gallup Office, Gallup, New Mexico, United States; Center for American Indian Health - Shiprock Office, Shiprock, New Mexico, United States; Vassar Brothers Medical Center, Poughkeepsie, New York, United States; University of Rochester, Rochester, New York, United States; University of Cincinnati Medical Center, Cincinnati, Ohio, United States; Lifespan/BrownUniversity (Rhode Island Hospital), Providence, Rhode Island, United States; Baylor College of Medicine, Houston, Texas, United States; University of Texas Health Science Center at Houston, Houston, Texas, United States; The University of Utah, Salt Lake City, Utah, United States
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Triple (Participant, Care Provider, Investigator), Primary Purpose: Treatment
- Enrollment -
180
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Efficacy of treatment at Day 28, Safety of treatment with high-titer Anti- SARS-CoV-2 plasma versus control - 1, Safety of treatment with high-titer Anti- SARS-CoV-2 plasma versus control - 2, Cumulative incidence of disease severity
|
NCT04421404
|
Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients |
Completed |
Phase 2 |
Jun/09/2020 |
Apr/30/2021 |
- Acronym - CAPRI
- Alternative id -
20-30794
- Interventions -
Biological: COVID-19 Convalescent Plasma (CCP), Biological: Placebo
- Study type - Interventional
- Study results -
Has Results
- Study locations -
San Francisco General Hospital, San Francisco, California, United States; UCSF Medical Center at Mount Zion, San Francisco, California, United States; University of California, San Francisco Medical Center (Parnassus Campus), San Francisco, California, United States
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Triple (Participant, Care Provider, Investigator), Primary Purpose: Treatment
- Enrollment -
34
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Mechanical Ventilation or Death Endpoint, 8-Point Ordinal Scale Endpoint
|
NCT04502472
|
Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma |
Terminated |
Phase 2|Phase 3 |
Jun/06/2020 |
Sep/30/2020 |
- Acronym - Inova-CCP
- Alternative id -
Inova COVID-19 CCP
- Interventions -
Biological: Convalescent plasma transfusion
- Study type - Interventional
- Study results -
Has Results
- Study locations -
Inova Fairfax Medical Campus, Falls Church, Virginia, United States
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
109
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Change is Clinical Status, Transfusion Related Events Due to Administration of CCP, Length of Hospital Stay, Mechanical Ventilation, Change in Mechanical Ventilation Status, Mortality
|
NCT04479163
|
Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2 |
Completed |
Not Applicable |
Jun/04/2020 |
Oct/25/2020 |
- Alternative id -
FundacionINFANT-Plasma
- Interventions -
Biological: Convalescent Plasma, Other: Placebo
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Hospital Militar Central, Caba, Buenos Aires, Argentina; CEMIC, Caba, Buenos Aires, Argentina; Centro de Investigacion Clinica OSECAC, Caba, Buenos Aires, Argentina; Centro Gallego de Buenos Aires, Caba, Buenos Aires, Argentina; Sanatorio Anchorena, Caba, Buenos Aires, Argentina; Sanatorio de Los Arcos, Caba, Buenos Aires, Argentina; Hospital "Simplemente Evita", González Catán, Buenos Aires, Argentina; Hospital Especializado de Agudos y Crónicos "San Juan de Dios", La Plata, Buenos Aires, Argentina; Clinica Olivos, Buenos Aires, Argentina; Hospital Central de San Isidro, Buenos Aires, Argentina; Hospital General de Agudos "Dr. Carlos Bocalandro", Buenos Aires, Argentina
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor), Primary Purpose: Prevention
- Enrollment -
165
- Age -
65 Years and older (Older Adult)
- Outcome measures -
Development of severe respiratory disease defined as a respiratory rate (RR)>30 and/or an O2 sat<93%, Life threatening respiratory disease, Critical systemic illness, defined as respiratory failure, Death, Combination of secondary outcomes #2 (Life threatening respiratory disease) and/or #3 (Critical systemic illness, defined as respiratory failure) and//or #4 (death), Duration of oxygen support requirement in patients with covid-19 due to saturation in ambient air <93%.
|
NCT04373460
|
Convalescent Plasma to Limit SARS-CoV-2 Associated Complications |
Active, not recruiting |
Phase 2 |
Jun/03/2020 |
Jan/31/2023 |
- Acronym - CSSC-004
- Alternative id -
IRB00247590
- Interventions -
Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
University of Alabama at Birmingham, Birmingham, Alabama, United States; Mayo Clinic, Phoenix, Phoenix, Arizona, United States; Center for American Indian Health - Whiteriver Office, Whiteriver, Arizona, United States; University of California, Los Angeles, Los Angeles, California, United States; University of California, Irvine Health, Orange, California, United States; Western Connecticut Health Netowrk, Danbury Hospital, Danbury, Connecticut, United States; Western Connecticut Health Network, Norwalk Hospital, Norwalk, Connecticut, United States; University of Miami, Coral Gables, Florida, United States; University of Miami Clinical Translational Research Site, Miami, Florida, United States; NorthShore University HealthSystem, Evanston, Illinois, United States; Anne Arundel Medical Center, Annapolis, Maryland, United States; The Johns Hopkins University, Baltimore, Maryland, United States; MedStar Washington Hospital Center, Hyattsville, Maryland, United States; University of Massachusetts Worcester, Worcester, Massachusetts, United States; Wayne State University, Detroit, Michigan, United States; University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States; Center for American Indian Health - Gallup Office, Gallup, New Mexico, United States; Center for American Indian Health - Shiprock Office, Shiprock, New Mexico, United States; Vassar Brothers Medical Center, Poughkeepsie, New York, United States; University of Rochester, Rochester, New York, United States; University of Cincinnati Medical Center, Cincinnati, Ohio, United States; Lifespan/BrownUniversity (Rhode Island Hospital), Providence, Rhode Island, United States; Baylor College of Medicine, Houston, Texas, United States; University of Texas Health Science Center at Houston, Houston, Texas, United States; The University of Utah, Salt Lake City, Utah, United States
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Triple (Participant, Care Provider, Investigator), Primary Purpose: Treatment
- Enrollment -
1344
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Cumulative incidence of hospitalization or death prior to hospitalization, Cumulative incidence of treatment-related serious adverse events, Cumulative incidence of treatment-related grade 3 or higher adverse events, Change in serum SARS-CoV-2 antibody titers, Time to SARS-CoV-2 Polymerase Chain Reaction (PCR) negativity
|
NCT04383548
|
Clinical Study for Efficacy of Anti-Corona VS2 Immunoglobulins Prepared From COVID19 Convalescent Plasma Prepared by VIPS Mini-Pool IVIG Medical Devices in Prevention of SARS-CoV-2 Infection in High Risk Groups as Well as Treatment of Early Cases of COVID19 Patients |
Not yet recruiting |
Not Applicable |
Jun/01/2020 |
Jan/01/2021 |
- Alternative id -
Mini-pooled IVIG in COVID19
- Interventions -
Other: hyper immunoglobulins containing anti-Corona VS2 immunoglobulin
- Study type - Interventional
- Study results -
No Results Available
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
100
- Age -
21 Years to 50 Years (Adult)
- Outcome measures -
Efficacy of COVID19 hyper immunoglobulins for patients, Efficacy of COVID19 hyper immunoglobulins for high risk groups, Safety of anti-SARS-CoV-2 hyper immunoglobulins assessed by percentage of adverse events
|
NCT04415086
|
Treatment of Patients With COVID-19 With Convalescent Plasma |
Active, not recruiting |
Phase 2 |
Jun/01/2020 |
May/22/2022 |
- Acronym - COOPCOVID-19
- Alternative id -
COOP-COVID-19-MCTIC
- Interventions -
Biological: convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
University of Sao Paulo - General Hospital, São Paulo, SP, Brazil
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
129
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Time elapsed until clinical improvement or hospital discharge, acute adverse events, Clinical Status, Duration of clinical events, SARS-CoV-2 in nasopharyngeal swab, IgG, IgM and IgA titers for SARS-CoV-2, Neutralizing antibodies
|
NCT04438694
|
Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection |
Recruiting |
Phase 1|Phase 2 |
Jun/01/2020 |
Dec/31/2021 |
- Acronym - CP IN COVID19
- Alternative id -
N39-2020
- Interventions -
Biological: Convalescent Plasma, Drug: Standard of Care
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Cairo University Hospital, Cairo, Egypt
- Study designs -
Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
67
- Age -
21 Years to 70 Years (Adult, Older Adult)
- Outcome measures -
Duration of hospitalization/Recovery status
|
NCT04412486
|
COVID-19 Convalescent Plasma (CCP) Transfusion |
Recruiting |
Early Phase 1 |
Jun/01/2020 |
May/31/2022 |
- Alternative id -
2020-0137
- Interventions -
Biological: COVID Convalescent Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
University of Mississippi Medical Center, Jackson, Mississippi, United States
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
100
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Change in PaO2/FiO2 after CCP transfusion., Change in pulse oximetry status after CCP transfusion., Change in aO2 after CCP transfusion., Change in respiratory rate after CCP transfusion., Change in intubation status after CCP transfusion., Change in Sequential Organ Failure Assessment (SOFA)., Change in 8-point ordinal clinical deterioration scale., Length of ICU/hospital stay., Development of plasma transfusion reactions., Development of immune complex disorders., Change in anti CoV-2 IgM and IgG levels.
|
NCT04391101
|
Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19) |
Not yet recruiting |
Phase 3 |
Jun/01/2020 |
Dec/01/2021 |
- Alternative id -
002
- Interventions -
Drug: Convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Hospital San Vicente Fundacion, Medellín, Antioquia, Colombia
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
231
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Intrahospital mortality from any cause, Length of hospital stay, Free time for ventilatory support on day 60, Overall survival at day 60 since hospitalization, Cumulative incidence of adverse events: transfusion reactions (fever, flare), TRALI (transfusion-associated lung injury), TACO (transfusion-related circulatory overload), transfusion- related infections
|
NCT04377672
|
Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19) |
Completed |
Phase 1 |
May/28/2020 |
Dec/13/2021 |
- Alternative id -
IRB00247557
- Interventions -
Biological: Anti-SARS-CoV-2 Human Convalescent Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Johns Hopkins Hospitals, Baltimore, Maryland, United States
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
14
- Age -
1 Month to 18 Years (Child, Adult)
- Outcome measures -
Safety of treatment with high-titer anti-SARS-CoV-2 plasma as assessed by adverse events, Proportion of subjects with disease worsening event, Pharmacokinetics of anti-SARS-CoV-2 antibodies as defined by changes in antibody titers, Proportion of subjects with a natural antibody response to SARS-CoV-2 infection
|
NCT04374526
|
Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression. |
Completed |
Phase 2|Phase 3 |
May/27/2020 |
May/26/2021 |
- Acronym - LIFESAVER
- Alternative id -
3205
- Interventions -
Biological: COVID-19 Convalescent Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, RM, Italy; Ospedale SS Annunziata, Chieti, Italy; Istituto Nazionale Malattie Infettive Lazzaro Spallanzani, Rome, Italy
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Prevention
- Enrollment -
29
- Age -
65 Years and older (Older Adult)
- Outcome measures -
Rate of COVID-19 progression
|
NCT04474340
|
COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients |
Recruiting |
Phase 1 |
May/21/2020 |
Dec/30/2020 |
- Alternative id -
MOHKuwait
- Interventions -
Drug: COVID-19 Convalscent Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Ministry Of Health, Kuwait, Kuwait
- Study designs -
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
300
- Age -
15 Years to 85 Years (Child, Adult, Older Adult)
- Outcome measures -
Time to clinical improvement, All cause mortality
|
NCT04405310
|
Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial |
Completed |
Phase 2 |
May/20/2020 |
Dec/10/2020 |
- Acronym - CPC-SARS
- Alternative id -
DI/20/201/04/19
- Interventions -
Biological: Convalescent Plasma of patients with COVID-19, Other: placebo (hartmann plus albumine)
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Hospital Nava de Alta Especialidad, Mexico City, Mexico; Hospital General de Mexico Dr Eduardo Liceaga, Mexico City, Mexico
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double (Participant, Care Provider), Primary Purpose: Treatment
- Enrollment -
42
- Age -
18 Years to 70 Years (Adult, Older Adult)
- Outcome measures -
Death, Lenth of stay ICU, Days of Mechanical Ventilation, Suplemental Oxigen support, Viral Load by RT-PCR, Inflamatory biomarkers, SOFA (sequencial Organ Failure Assesment)
|
NCT04356482
|
CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19 |
Recruiting |
Phase 1|Phase 2 |
May/20/2020 |
Dec/01/2020 |
- Acronym - COPLASCOV19
- Alternative id -
TERAPLASCOV2
- Interventions -
Biological: convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Hospital Del Issste Regional En Guadalajara Jalisco, Guadalajara, Jalisco, Mexico; Secretaria de Salud Del Estado de Sonora, Hospital General Del Estado, Hermosillo, Sonora, Mexico; Hospital Central Norte Pemex, Mexico City, Mexico
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
90
- Age -
16 Years and older (Child, Adult, Older Adult)
- Outcome measures -
Clinical improvement, improvement in tomographic image, test positivity for COVID-19, early and late complications associated to convalescent plasma, days at ICU
|
NCT04403477
|
Convalescent Plasma Therapy in Severe COVID-19 Infection |
Recruiting |
Phase 2 |
May/20/2020 |
Oct/30/2020 |
- Alternative id -
BSMMU/2020/6104
- Interventions -
Biological: Convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
20
- Age -
16 Years and older (Child, Adult, Older Adult)
- Outcome measures -
Proportion of In-hospital mortality, Time to death, Fever, Respiratory distress, Saturation of oxygen, Blood pressure, Oxygen requirement, C-reactive Protein, Ferritin, SGPT, SGOT, ICU stay, Ventilator support, Hospital stay, Proportion of Transfusion reaction
|
NCT04380935
|
Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome |
Recruiting |
Phase 2|Phase 3 |
May/18/2020 |
Oct/31/2020 |
- Alternative id -
convalescent plasma RSCM-FKUI
- Interventions -
Biological: Convalescent plasma, Drug: Standard of care
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Dr. Cipto Mangunkusumo General Hospital, Jakarta, DKI Jakarta, Indonesia; St. Carolus Hospital, Jakarta, DKI Jakarta, Indonesia; Ciputra Hospital CitraRaya, Jakarta, DKI Jakarta, Indonesia
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
60
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
All-cause mortality, Length of stay in intensive care unit, Duration of mechanical ventilation, Body temperature (degree in Celsius), The Sequential Organ Failure Assessment (SOFA) Score, PAO2/FIO2 ratio, C-Reactive Protein (CRP) in mg/L, D-Dimer in ng/mL, Procalcitonin in ng/mL, Interleukin 6 (IL-6) in pg/mL, Allergic/ anaphylaxis transfusion reaction, Hemolytic transfusion reaction, Transfusion Related Acute Lung Injury, Transfusion associated Circulatory Overload
|
NCT04383535
|
Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia |
Completed |
Not Applicable |
May/15/2020 |
Sep/27/2020 |
- Acronym - PLASM-AR
- Alternative id -
5565
- Interventions -
Other: Convalescent SARS COVID-19 plasma, Other: Placebo
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor), Primary Purpose: Treatment
- Enrollment -
333
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Clinical status during follow-up at 30th day, Clinical status during follow-up at 7th day, Clinical status during follow-up at 14th day, Time until hospital discharge (days)., Time until discharge from ICU (days), Time to death, Time until complete functional recovery, Percentage of participants with adverse events / serious adverse events, Percentage of patients with negative SARS-CoV-3 PCR at Day 14th, D Dimer plasma concentration at Day 14th, Ferritin plasma concentration at Day 13th, Plasma concentration of neutralizing antibodies at Day 2nd, Plasma concentration of neutralizing antibodies at Day 7th, Post-transfusion adverse reactions
|
NCT04569188
|
Convalescent Plasma in COVID-19 Elderly Patients |
Completed |
Phase 2 |
May/15/2020 |
Sep/03/2020 |
- Acronym - RESCUE
- Alternative id -
Asstmantova
- Interventions -
Biological: Convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Transfusion Service, Mantova, Italy
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
21
- Age -
65 Years and older (Older Adult)
- Outcome measures -
Death, Viral load
|
NCT04397757
|
COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2. |
Completed |
Phase 1 |
May/13/2020 |
Mar/08/2021 |
- Alternative id -
843003 (PennCCP-02)
- Interventions -
Biological: COVID-19 Convalescent Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
80
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Participants with serious adverse events., Comparison of clinical severity score between patients on the experimental versus control arms;, Clinical status assessment, using 8-point ordinal scale, of convalescent plasma administration by comparing treatment vs control arms, Clinical status assessment using the National Early Warning Score (NEWS) of convalescent plasma administration by comparing treatment vs control arms, Oxygen-free days of convalescent plasma administration by comparing treatment vs control arms, Incidence of new oxygenation use up to Day 29 of convalescent plasma administration by comparing treatment vs control arms, Duration of new oxygen use up to Day 29 of convalescent plasma administration by comparing treatment vs control arms, Non-invasive ventilation/high flow oxygen days up to Day 29 of convalescent plasma administration by comparing treatment vs control arms, Incidence of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration by comparing treatment vs control arms, Duration of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration by comparing treatment vs control arms, Ventilator/ECMO free days to Day 29 of convalescent plasma administration by comparing treatment vs control arms, Incidence of new mechanical ventilation or ECMO use of convalescent plasma administration by comparing treatment vs control arms, Duration of new mechanical ventilation or ECMO use of convalescent plasma administration by comparing treatment vs control arms, Duration of hospitalization of convalescent plasma administration by comparing treatment vs control arms, Mortality of convalescent plasma administration by comparing treatment vs control arms, Cumulative incidence of SAEs through Day 29 of convalescent plasma administration by comparing treatment vs control arms, Cumulative incidence of Grade 3 and Grade 4 clinical and/or laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms, Changes in WBC with differential through day 29 of convalescent plasma administration by comparing treatment vs control arms, Changes in hemoglobin measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms, Changes in platelets measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms, Changes in creatinine measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms, Changes in glucose measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms, Changes in bilirubin measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms, Changes in ALT measurement laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms, Changes in AST measurement through Day 29 of convalescent plasma administration by comparing treatment vs control arms, Changes in PT measurement laboratory adverse events through Day 29 of convalescent plasma administration by comparing treatment vs control arms
|
NCT04354831
|
A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection |
Active, not recruiting |
Phase 2 |
May/11/2020 |
May/01/2023 |
- Alternative id -
PRO00037712
- Interventions -
Biological: anti-SARS-CoV-2 convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Froedtert Hospital, Milwaukee, Wisconsin, United States
- Study designs -
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
131
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Overall Mortality within 60 days, Length of ICU stay during current admission for COVID
|
NCT04374487
|
Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications |
Active, not recruiting |
Phase 2 |
May/09/2020 |
Aug/09/2021 |
- Alternative id -
MHC-COVID-19-CP
- Interventions -
Drug: Convalescent Plasma, Other: Standard Care Therapy
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
100
- Age -
18 Years to 85 Years (Adult, Older Adult)
- Outcome measures -
The primary outcome is a composite measure of the avoidance of - 1. Progression to severe ARDS (P/F ratio 100) and 2. All-cause Mortality at 28 days, Time to symptom resolution-Fever,Shortness of Breath,Fatigue, Hospital length of stay, Change in SOFA pre and post transfusion, Duration of respiratory support required a. Duration of Invasive Mechanical Ventilation b. Duration of Non-Invasive, Radiological improvement, Adverse events (AE) associated with transfusion, To measure the change in RNA levels (Ct values) of SARS-CoV-2 from RT-PCR [Time Frame: Days 0, 1, 3, and 7 after transfusion], Levels of bio-markers pre and post transfusion, Need of Vasopressor use
|
NCT04333355
|
Safety in Convalescent Plasma Transfusion to COVID-19 |
Terminated |
Phase 1 |
May/08/2020 |
Aug/20/2020 |
- Alternative id -
PC-TecSalud Fase I
- Interventions -
Biological: Convalescent Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Hospital San José, Monterrey, Nuevo Leon, Mexico
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
12
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Side effects, Heart Failure, Pulmonary Edema, Allergic Reaction, Viral load of SARS-CoV-2
|
NCT04384497
|
Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study |
Completed |
Phase 1|Phase 2 |
May/07/2020 |
Dec/01/2020 |
- Alternative id -
CP2
- Interventions -
Biological: SARS-CoV-2 convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Danderyd Hospital, Danderyd, Stockholm, Sweden; Karolinska University Hospital, Stockholm, Sweden
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
10
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Number and proportion of patients with progression to ventilation or sustained requirement of supplementary oxygen therapy, Adverse events, Dose of plasma needed to clear viremia, Clearance of viremia, Fever and symptoms, Inflammatory parameters, Antibody response to SARS-CoV-2
|
NCT04381858
|
Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia |
Completed |
Phase 3 |
May/06/2020 |
Nov/26/2020 |
- Alternative id -
2020-A-10
- Interventions -
Drug: Plasma from COVID-19 convalescent patient, Drug: Human immunoglobulin
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double (Participant, Outcomes Assessor), Primary Purpose: Treatment
- Enrollment -
196
- Age -
16 Years to 90 Years (Child, Adult, Older Adult)
- Outcome measures -
Mean hospitalization time, Mean Oxigenation index evolution, Rate of severe ARDS, Rate and time to dead, Mean time with invasive mechanical ventilation, Time to Viral PCR Negativization
|
NCT04392232
|
A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection |
Completed |
Phase 2 |
May/05/2020 |
Sep/21/2021 |
- Alternative id -
20-045
- Interventions -
Drug: Convalescent Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Good Samaritan Hospital, Cincinnati, Ohio, United States; Bethesda North Hospital, Cincinnati, Ohio, United States
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
159
- Age -
16 Years and older (Child, Adult, Older Adult)
- Outcome measures -
Survival Rate
|
NCT04374565
|
Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia |
Active, not recruiting |
Phase 2 |
May/05/2020 |
Apr/05/2021 |
- Alternative id -
200114
- Interventions -
Drug: High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
University of Virginia Medical Center, Charlottesville, Virginia, United States; University of Virginia, Charlottesville, Virginia, United States
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
29
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Transfer to ICU, 28 day mortality, Cumulative incidence of serious adverse events, Rates and duration of SARS-CoV-2, Serum of plasma antibody titer to SARS-CoV-2, Cellular and humoral immune response, Supplemental oxygen free days, Ventilator free days, ICU free days, Sequential organ failure assessment score, Need for vasopressors, Need for renal replacement therapy, Need for extracorporeal membrane oxygenation (ECMO), Hospital length of stay (LOS), ICU LOS, Grade 3 or 4 Adverse Events (AEs)
|
NCT04442191
|
Convalescent Plasma as a Possible Treatment for COVID-19 |
Recruiting |
Phase 2 |
May/05/2020 |
May/05/2021 |
- Alternative id -
2020-0441
- Interventions -
Biological: Convalescent plasma, Biological: Placebo
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
University of Illinois at Chicago, Chicago, Illinois, United States
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Triple (Participant, Investigator, Outcomes Assessor), Primary Purpose: Treatment
- Enrollment -
50
- Age -
40 Years and older (Adult, Older Adult)
- Outcome measures -
Oxygen supplementation, 28-day and in-hospital mortality rate, Number of participants transferred to the Intensive Care Unit (ICU), Number of participants intubated, Length of hospital stay in days, Type of respiratory support, C-reactive Protein (CRP), Lymphocyte count, Length or respiratory support required, in days, Lactate dehydrogenase (LDH), Ferritin, D-Dimer, White Blood Cell (WBC) Count
|
NCT04385199
|
Convalescent Plasma for Patients With COVID-19 |
Completed |
Phase 2 |
May/04/2020 |
Aug/01/2020 |
- Alternative id -
13807
- Interventions -
Biological: Convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Henry Ford Hospital, Detroit, Michigan, United States
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
30
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Improvement in respiratory disease, ICU Length of Stay, Length of Stay, Ventilator days, Tolerability of convalescent plasma, Radiographic improvement
|
NCT04375098
|
Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection |
Completed |
Phase 2 |
May/04/2020 |
Aug/17/2020 |
- Alternative id -
200415015
- Interventions -
Biological: COVID-19 convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Hospital Clínico Universidad Católica, Santiago, Chile
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
58
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Percentage Mechanical Ventilation, hospitalization longer than 14 days or death during hospitalization, Median duration of fever, Median duration of mechanical ventilation, Median length of ICU stay, Median length of admission, Hospital mortality rate (percentage), 30-day mortality (percentage), Readmission rate (percentage), Median length of viral clearance
|
NCT04429854
|
Donated Antibodies Working Against nCoV |
Completed |
Phase 2 |
May/02/2020 |
Apr/30/2021 |
- Acronym - DAWN-Plasma
- Alternative id -
S63992
- Interventions -
Biological: Convalescent Plasma, Drug: Standard of care
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
ZNA, Antwerpen, Belgium; Imelda Ziekenhuis Bonheiden, Bonheiden, Belgium; Institut Bordet, Brussel, Belgium; UMC Sint-Pieter, Brussel, Belgium; CHU Brugmann, Brussel, Belgium; Erasmus Ziekenhuis, Brussel, Belgium; UZ Brussel, Brussel, Belgium; Cliniques Universitaires St Luc, Brussel, Belgium; AZ Sint-Vincentius, Deinze, Belgium; AZ Maria Middelares, Gent, Belgium; AZ Sint-Lucas, Gent, Belgium; AZ Groeninge, Kortrijk, Belgium; UZ Leuven, Leuven, Belgium; CHC Liège Mont Légia, Liège, Belgium; CHR Citadelle Liège, Liège, Belgium; CHU Liège Sart-Tilman, Liège, Belgium; CHU Ambroise Paré, Mons, Belgium; CHR Jolimont Mons-Hainaut, Mons, Belgium; AZ Delta, Roeselare, Belgium; Sint-Trudo Ziekenhuis, Sint-Truiden, Belgium; Centre Hospitalier de Wallonie Picarde (CHwapi), Tournai, Belgium
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
483
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Patients requiring mechanical ventilation or death, Clinical status of subject at day 15 and day 30 (on a 10-point "WHO progression" ordinal scale)
|
NCT04392414
|
Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease |
Completed |
Phase 2 |
May/01/2020 |
Sep/23/2020 |
- Alternative id -
CovPlas-Covid19
- Interventions -
Biological: COVID-19 convalescent hyperimmune plasma, Biological: Non-convalescent fresh frozen plasma (Standard plasma)
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Federal Research Clinical Center of Federal Medical & Biological Agency, Moscow, Russian Federation
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
60
- Age -
18 Years to 75 Years (Adult, Older Adult)
- Outcome measures -
The number and proportion of patients with the normal body temperature (≤37.2 C) at the day 1, 2, 3, 4, 5, 6, 7 after the start of therapy, Days before mechanical ventilation, Days of need for oxygen therapy, Days of stay in the ICU, Days of hospitalization, Changes of the titer of the SARS-CoV-2 antibodies in the blood plasma of patients, Dynamics of the cytokine profile, Incidence of the cytokine storm development and the need of administering cytokine storm inhibitors, Dynamics of the level of C-reactive protein, 30-day mortality rate
|
NCT04545047
|
Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19 |
Active, not recruiting |
|
May/01/2020 |
Jun/30/2022 |
- Alternative id -
2030
- Interventions -
Biological: COVID-19 convalescent plasma
- Study type - Observational
- Study results -
No Results Available
- Study locations -
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States; VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States
- Study designs -
Observational Model: Other, Time Perspective: Prospective
- Enrollment -
4755
- Age -
21 Years to 80 Years (Adult, Older Adult)
- Outcome measures -
All-cause mortality
|
NCT04352751
|
Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020 |
Recruiting |
Not Applicable |
May/01/2020 |
Apr/01/2021 |
- Alternative id -
PIPK- 0000 /NIBD-0000/2020
- Interventions -
Other: convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
National Institute of Blood Diseases and Bone Marrow Transplantation (NIBD), Karachi, Sindh, Pakistan
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Other
- Enrollment -
2000
- Age -
18 Years to 55 Years (Adult)
- Outcome measures -
Change in COVID-19 severity status
|
NCT04407208
|
Convalescent Plasma Therapy in Patients With COVID-19 |
Completed |
Phase 1 |
May/01/2020 |
Jun/22/2020 |
- Alternative id -
3471041S322342020040800002
- Interventions -
Biological: Convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Gatot Soebroto central army presidential hospital, Jakarta Pusat, Indonesia
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Health Services Research
- Enrollment -
10
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Plaque reduction neutralization test (PNRT), D-dimer, C-Reactive Protein (CRP), International Normalized Ratio (INR), Oxygenation Index, Chest X-ray, severe adverse event
|
NCT04332380
|
Convalescent Plasma for Patients With COVID-19: A Pilot Study |
Completed |
Phase 2 |
May/01/2020 |
Jul/28/2020 |
- Acronym - CP-COVID-19
- Alternative id -
ABN011-1
- Interventions -
Drug: Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Universidad del Rosario, Bogota, Cundinamarca, Colombia
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
10
- Age -
18 Years to 60 Years (Adult)
- Outcome measures -
Change in Viral Load, Change in Immunoglobulin M COVID-19 antibodies Titers, Change in Immunoglobulin G COVID-19 antibodies Titers, Intensive Care Unit Admission, Length of Intensive Care Unit stay, Length of hospital stay (days), Requirement of mechanical ventilation, Duration (days) of mechanical ventilation, Clinical status assessed according to the World Health Organization guideline, Mortality
|
NCT04565197
|
Convalescent Plasma Therapy for COVID-19 Patients |
Active, not recruiting |
Early Phase 1 |
May/01/2020 |
Dec/30/2020 |
- Alternative id -
LGH008
- Interventions -
Biological: convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Muhammad Irfan Malik, Lahore, Punjab, Pakistan
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
20
- Age -
15 Years to 80 Years (Child, Adult, Older Adult)
- Outcome measures -
clinical outcome after plasma therapy, Clinical response to treatment
|
NCT04393727
|
Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19 |
Terminated |
Phase 2 |
May/01/2020 |
Sep/30/2020 |
- Acronym - TSUNAMI
- Alternative id -
TSUNAMI
- Interventions -
Biological: CONVALESCENT PLASMA
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
1
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Need of invasive mechanical ventilation, Mortality rates, Time to invasive mechanical ventilation, Time to virologic cure, Length of hospital stay, Adverse events
|
NCT04361253
|
Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy |
Terminated |
Phase 3 |
Apr/30/2020 |
Jun/30/2021 |
- Acronym - (ESCAPE)
- Alternative id -
2020P001215
- Interventions -
Biological: High-Titer COVID-19 Convalescent Plasma (HT-CCP), Biological: Standard Plasma (FFP)
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Brigham and Women's Hospital, Boston, Massachusetts, United States
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double (Participant, Investigator), Primary Purpose: Treatment
- Enrollment -
45
- Age -
12 Months and older (Child, Adult, Older Adult)
- Outcome measures -
Modified WHO Ordinal Scale (MOS) score
|
NCT04397523
|
Efficacy and Safety of COVID-19 Convalescent Plasma |
Completed |
Not Applicable |
Apr/30/2020 |
May/10/2021 |
- Alternative id -
ITM05/2020MKD
- Interventions -
Biological: anti-SARS-CoV-2 convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Institute for Transfusion Medicine of RNM, Skopje, North Macedonia
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
200
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Duration of oxygenation and ventilation support, Hospital length of stay (LOS), ICU admission, Ventilator free days, Incidence of serious adverse events, Type of respiratory support, Number of participants with different clinical outcomes including death, critical illness and recovery
|
NCT04388527
|
COVID-19 Convalescent Plasma for Mechanically Ventilated Population |
Completed |
Phase 1 |
Apr/30/2020 |
Jan/30/2021 |
- Alternative id -
842996 (PennCCP-01)
- Interventions -
Biological: COVID-19 Convalescent Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
32
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Participants with serious adverse events., Time to clinical improvement., Clinical status assessment, using 8-point ordinal scale, of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006., Clinical status assessment using the National Early Warning Score (NEWS) of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006., Incidence of new oxygenation use up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006., Duration of new oxygen use up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006., Oxygen-free days of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006., Non-invasive ventilation/high flow oxygen days up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006., Incidence of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006., Duration of non-invasive ventilation/high flow oxygen up to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006., Ventilator/ECMO free days to Day 29 of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006., Incidence of new mechanical ventilation or ECMO use of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006., Duration of new mechanical ventilation or ECMO use of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006., Duration of hospitalization of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006, Mortality of convalescent plasma administration as compared to placebo recipients in DMID Protocol Number: 20-0006, Cumulative incidence of SAEs through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006., Cumulative incidence of Grade 3 and Grade 4 clinical and/or laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006., Changes in WBC with differential through day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006., Changes in hemoglobin measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006., Changes in platelets measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.., Changes in creatinine measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.., Changes in glucose measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006., Changes in bilirubin measurement through Day 29 of convalescent plasma administration as compared to matched participants form the control arm of DMID Protocol No. 20-0006.., Changes in ALT measurement laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006., Changes in AST measurement through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006., Changes in PT measurement laboratory adverse events through Day 29 of convalescent plasma administration as compared to matched participants from the control arm of DMID Protocol No. 20-0006.
|
NCT04471051
|
An Observational Cohort Trial of Outcomes and Antibody Responses Following Treatment With COVID19 Convalescent Plasma in Hospitalized COVID-19 Patients |
Completed |
|
Apr/30/2020 |
Aug/20/2020 |
- Alternative id -
20-0986
- Study type - Observational
- Study results -
No Results Available
- Study locations -
Children's Hospital Colorado, Aurora, Colorado, United States; University of Colorado Hospital, Aurora, Colorado, United States; UCHealth Memorial Hospital North, Colorado Springs, Colorado, United States; Denver Health Medical Center, Denver, Colorado, United States; UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States; UCHealth Highlands Ranch Hospital, Highlands Ranch, Colorado, United States
- Study designs -
Observational Model: Cohort, Time Perspective: Prospective
- Enrollment -
255
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Inpatient Mortality, Requirement for mechanical ventilation, Transfer to ICU, ICU Mortality, ICU Length of Stay (LOS), Hospital Mortality, Hospital Length of Stay (LOS)
|
NCT04869072
|
Convalescent Plasma Therapy - Zurich Protocol |
Completed |
Phase 1 |
Apr/29/2020 |
Mar/30/2021 |
- Acronym - CPT-ZHP
- Alternative id -
2020-00787
- Interventions -
Drug: Convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
University Hospital Zurich, Zürich, Switzerland
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
30
- Age -
Child, Adult, Older Adult
- Outcome measures -
Safety of CPT applied to COVID-19 patients, Improvement of respiratory frequency, Improvement of O2-saturation, Improvement of Inflammatory markers (C Reactive Protein, CRP), Improvement of Inflammatory markers (Ferritin), Improvement of Inflammatory markers (IL-6), Improvement of coagulation-markers (D-dimer), Improvement of coagulation-markers (Fibrinogen), Improvement of coagulation-markers (LDH), Prevention of ICU-admission, Characterisation of virus reaction to plasma Therapy, Characterisation of the dynamic of humoral response after therapy, Better characterize the the in-vivo anti-virus humoral response against SARS-CoV-2.
|
NCT04434131
|
Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19 |
Recruiting |
Phase 2 |
Apr/28/2020 |
Apr/28/2025 |
- Alternative id -
20-227
- Interventions -
Drug: Convalescent Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Prevention
- Enrollment -
30
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Correlation between the NAb dose titer in the convalescent plasma and change or lack of change when comparing pre-treatment and day one NAb titers to inpatients with documented COIVD-19 infection, Rapid deterioration as evidenced by increase in ordinal or news score within 4 hours of transfusion, Number of participants with clearance of viral shedding of SARSCoV-2 in nasopharyngeal or nasal samples
|
NCT04358783
|
Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia |
Completed |
Phase 2 |
Apr/27/2020 |
May/01/2021 |
- Acronym - COP-COVID-19
- Alternative id -
IF20-00002
- Interventions -
Biological: Plasma, Other: Best Available Therapy
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Hospital Universitario José E. Gonzalez, Monterrey, Nuevo Leon, Mexico
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor), Primary Purpose: Treatment
- Enrollment -
31
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Early all-cause mortality, Time in days for SARS-CoV-2 RT-PCR negatives, The serum anti-SARS-CoV-2 antibody titres, Detection of serum antibodies
|
NCT04476888
|
Convalescent Plasma Treatment in COVID-19 |
Completed |
Not Applicable |
Apr/26/2020 |
Oct/10/2020 |
- Acronym - COLLATE
- Alternative id -
CON000000000880
- Interventions -
Biological: Convalescent Plasma (CP), Other: Drugs and supportive care
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Aga Khan University Hospital, Karachi, Sind, Pakistan
- Study designs -
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
110
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Decrease length of stay, Overall mortality, Incidence of adverse events related to Convalescent Plasma transfusion, Ordinal scale, Improvement in Laboratory Parameters: Serum Ferritin, Improvement in Laboratory Parameters: Procalcitonin, Improvement in Laboratory Parameters: C-Reactive Protein, Improvement in Laboratory Parameters: D-Dimer, Improvement in Laboratory Parameters: Complete Blood count, Chest X-Ray findings
|
NCT04600440
|
Convalescent Plasma in the Treatment of Covid-19 |
Recruiting |
Not Applicable |
Apr/25/2020 |
Feb/28/2022 |
- Acronym - COP20
- Alternative id -
Covid convalescent plasma
- Interventions -
Biological: Convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Skåne University Hospital, Lund, Sweden
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
100
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Number of days in need of oxygen, Number of days before discharge from hospital, Mortality within 3 months, Number of days before need of assisted ventilation
|
NCT04362176
|
Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults |
Completed |
Phase 3 |
Apr/24/2020 |
Aug/06/2021 |
- Acronym - PassItOn
- Alternative id -
200738, 3UL1TR002243-04S3
- Interventions -
Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States; Scripps Health, La Jolla, California, United States; University of Colorado Denver, Aurora, Colorado, United States; MedStar Health Research Institute/MedStar Washington Hospital Center, Washington, District of Columbia, United States; Cleveland Clinic Florida, Weston, Florida, United States; University of Chicago, Chicago, Illinois, United States; Loyola University Medical Center, Maywood, Illinois, United States; The University of Kansas Medical Center, Kansas City, Kansas, United States; Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, United States; University of Maryland, Baltimore (University of Maryland Medical Center), Baltimore, Maryland, United States; Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States; Newton-Wellelsey Hospital, Newton, Massachusetts, United States; University of Minnesota, Minneapolis, Minnesota, United States; University of Mississippi Medical Center, Jackson, Mississippi, United States; University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States; University at Buffalo/Buffalo General Medical Center, Buffalo, New York, United States; Rochester General Hospital, Rochester, New York, United States; Cleveland Clinic Ohio, Cleveland, Ohio, United States; The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, Ohio, United States; Vanderbilt University Medical Center, Nashville, Tennessee, United States; Meharry Medical College, Nashville, Tennessee, United States; Utah Valley Hospital, Provo, Utah, United States; University of Utah Health, Salt Lake City, Utah, United States; Sentara Norfolk General Hospital, Norfolk, Virginia, United States; Virginia Commonwealth University, Richmond, Virginia, United States; University of Washington, Seattle, Washington, United States
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Triple (Participant, Care Provider, Outcomes Assessor), Primary Purpose: Treatment
- Enrollment -
974
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
COVID-19 7-point Ordinal Clinical Progression Outcomes Scale, All-location, all-cause 14-day mortality, All-location, all-cause 28-day mortality, Survival through 28 days, Time to hospital discharge through 28 days, COVID-19 7-point Ordinal Clinical Progression Outcomes Scale on Study Day 3, COVID-19 7-point Ordinal Clinical Progression Outcomes Scale on Study Day 8, COVID-19 7-point Ordinal Clinical Progression Outcomes Scale on Study Day 29, Oxygen-free days through Day 28, Ventilator-free days through Day 28, Vasopressor-free days through Day 28, ICU-free days through Day 28, Hospital-free days through Day 28
|
NCT04816942
|
Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt |
Completed |
Phase 3 |
Apr/23/2020 |
Oct/12/2020 |
- Alternative id -
10-2020/13
- Interventions -
Biological: Convalescent Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Ministry of Health, Cairo, Giza, Egypt
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
102
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
COVID-19 Cure rate
|
NCT04408209
|
Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection |
Recruiting |
Not Applicable |
Apr/23/2020 |
Sep/15/2021 |
- Alternative id -
245-14-4-20
- Interventions -
Procedure: Convalescent Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
"Evangelismos" General Hospital, Athens, Attiki, Greece; "Agios Savas" Oncology Hospital, Athens, Attiki, Greece; "Alexandra" General Hospital, Athens, Attiki, Greece; "Sotiria" General Hospital, Athens, Attiki, Greece; Attikon" University General Hospital, Athens, Chaidari, Greece; University General Hospital of Patras, Patra, Rio, Greece
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
60
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Survival, Clinical improvement ie percentage of patients not fulfilling the criteria for severe disease
|
NCT04359810
|
Plasma Therapy of COVID-19 in Severely Ill Patients |
Completed |
Phase 2 |
Apr/21/2020 |
Dec/30/2020 |
- Alternative id -
AAAS9924
- Interventions -
Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma), Biological: Non-convalescent Plasma (control plasma)
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Columbia University Irving Medical Center/NYP, New York, New York, United States; Hospital Federal dos Servidores do Estado, Rio De Janeiro, Brazil; Hospital Geral de Nova Iguaçu, Rio De Janeiro, Brazil; Instituto Nacional de Infectologia Evandro Chagas, Rio De Janeiro, Brazil
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double (Participant, Outcomes Assessor), Primary Purpose: Treatment
- Enrollment -
223
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Day 28 severity outcome, Proportion of SARS-CoV-2 PCR Positivity, Levels of SARS-CoV-2 RNA, Duration of Need for Supplemental Oxygen, Duration of Hospitalization, In-hospital and 28-day mortality, Time-to-clinical improvement in-hospital, Host genetic differences at day 0, Host transcriptomic differences at days 0,7,14
|
NCT04346446
|
Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients |
Completed |
Phase 2 |
Apr/20/2020 |
May/30/2020 |
- Alternative id -
ILBS-COVID-02
- Interventions -
Drug: Convalescent Plasma Transfusion, Other: Supportive Care, Drug: Random Donor Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Maulana Azad medical College, New Delhi, Delhi, India; Institute of Liver and Biliary Sciences, New Delhi, Delhi, India
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
29
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Proportion of patients remaining free of mechanical ventilation in both groups, Mortality in both groups, Improvement in Pa02/Fi02 ratio in both groups, Improvement in SOFA score in both groups, Duration of hospital Stay in both group., Duration of Intensive Care Unit stay in both groups., Requirements of Vasopressor in both groups., Days free of dialysis in both groups.
|
NCT04356534
|
Convalescent Plasma Trial in COVID -19 Patients |
Completed |
Not Applicable |
Apr/19/2020 |
Jul/09/2020 |
- Alternative id -
BDF/R&REC/2020-423
- Interventions -
Other: plasma therapy using convalescent plasma with antibody against SARS-CoV-2, Other: Routine care for COVID-19 patients
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
40
- Age -
21 Years and older (Adult, Older Adult)
- Outcome measures -
Requirement for invasive ventilation, Change in viral clearance, Radiological change, Change in white cell count, C reactive protein measurement, lactate dehydrogenase measurement, Procalcitonin measurement, D Dimer measurement, Ferritin measurement, Troponin T measurement, Brain naturetic peptide measurement, Mortality rate
|
NCT04535063
|
Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia |
Recruiting |
Phase 3 |
Apr/18/2020 |
Feb/25/2021 |
- Alternative id -
RValentini
- Interventions -
Biological: COVID19 convalescent plasma infusion
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
200
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
28 days survival, efficacy of plasma infusion according to antibodies levels in the infuse bags, clinical efficacy of plasma infusion according to frame time from symptoms onset and hospitalization, change in clinical WHO ordinal scale from 1 to 10 points
|
NCT04347681
|
Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19 |
Completed |
Phase 2 |
Apr/18/2020 |
Nov/16/2020 |
- Alternative id -
HAEM0321
- Interventions -
Other: convalescent plasma from recovered COVID 19 donor
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
John Hopkins Aramco Healthcare, Dhahran, Eastern Provence, Saudi Arabia; Dammam Medical Complex, Dammam, Saudi Arabia; Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; king Fahad specialist hospital, Dammam, Saudi Arabia; DHahran Military Medical Complex, Dhahran, Saudi Arabia; International Medical Center, Jeddah, Saudi Arabia; Madinah General Hospital, Medina, Saudi Arabia; Ohud Hospital, Medina, Saudi Arabia; Taibah University, Medina, Saudi Arabia; Qatif Central Hospital, Qatif, Saudi Arabia; King Abdulaziz Medical City, Riyadh, Saudi Arabia; King Fahad Medical City, Riyadh, Saudi Arabia; King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia; King Khalid University Hospital, Riyadh, Saudi Arabia
- Study designs -
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
575
- Age -
18 Years to 85 Years (Adult, Older Adult)
- Outcome measures -
ICU length of stay, Safety of convalescent plasma & Serious adverse reactions., Number of days on mechanical ventilation, 30 days of mortality, Days to clinical recovery .
|
NCT04364737
|
CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients |
Active, not recruiting |
Phase 2 |
Apr/17/2020 |
Dec/31/2022 |
- Alternative id -
20-00541
- Interventions -
Biological: Convalescent Plasma, Other: Saline solution
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Yale University School of Medicine, New Haven, Connecticut, United States; University of Miami Hospital and Clinics, Miami, Florida, United States; Montefiore Medical Center, Bronx, New York, United States; NYU Langone Health, New York, New York, United States; University of Texas Rio Grande Valley, Edinburg, Texas, United States; The University of Texas Health Science Center, Houston, Texas, United States; The University of Texas Health Science Center, Tyler, Texas, United States; Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States; Medical College of Wisconsin / Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double (Participant, Investigator), Primary Purpose: Treatment
- Enrollment -
384
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Score on the WHO 11-point ordinal scale for clinical improvement at 14 days, Score on the WHO 11-point ordinal scale for clinical improvement at 28 days
|
NCT04376034
|
Convalescent Plasma Collection and Treatment in Pediatrics and Adults |
Recruiting |
Phase 3 |
Apr/16/2020 |
Mar/30/2021 |
- Alternative id -
2004965705
- Interventions -
Biological: Convalescent Plasma 1 Unit, Biological: Convalescent Plasma 2 Units, Other: Standard of Care
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
WVU Medicine, Morgantown, West Virginia, United States
- Study designs -
Allocation: Non-Randomized, Intervention Model: Sequential Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
240
- Age -
31 Days and older (Child, Adult, Older Adult)
- Outcome measures -
Plasma Donor, Plasma Recipient
|
NCT04345991
|
Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort |
Completed |
Phase 2 |
Apr/15/2020 |
May/28/2021 |
- Acronym - CORIPLASM
- Alternative id -
APHP200375-10, 2020-001246-18
- Interventions -
Drug: Transfusion of COVID-19 convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
SMIT, Saint Antoine hospital, Paris, France
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
120
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Survival without needs of ventilator utilization or use of immunomodulatory drugs (other than steroids), WHO progression scale ≥6, Severe adverse events, WHO progression scale, Overall survival, Time from randomization to discharge, Time to oxygen supply independency, Survival without needs of ventilator utilization, Survival without use of immunomodulatory drugs
|
NCT04389710
|
Convalescent Plasma for the Treatment of COVID-19 |
Completed |
Phase 2 |
Apr/15/2020 |
Dec/07/2020 |
- Alternative id -
20D.379
- Interventions -
Drug: Convalescent Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
52
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Number of patients who receive COVID-19 convalescent plasma transfusions in acute care facilities infected with SARS-CoV-2, Number and type of adverse events associated with COVID-19 convalescent plasma in patients with COVID-19, Length of hospital stay, Length of Intensive Care Unit stay, Length of intubation, Survival to discharge, Changes in complete blood count in patients after receiving convalescent plasma, Abnormal changes in Basic Metabolic Panel (BMP) measures in patients after receiving convalescent plasma, Changes in C-Reactive Protein (CRP) in patients after receiving convalescent plasma, Changes in d-dimer in patients after receiving convalescent plasma, Changes in fibrinogen in patients after receiving convalescent plasma, Changes in prothrombin time (PT) in patients after receiving convalescent plasma, Changes in partial thromboplastin time (PTT) in patients after receiving convalescent plasma
|
NCT04345679
|
Anti COVID-19 Convalescent Plasma Therapy |
Recruiting |
Early Phase 1 |
Apr/14/2020 |
Sep/01/2021 |
- Alternative id -
AntiCOVID19ORT
- Interventions -
Biological: anti-SARS-CoV-2 convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Semmelweis University's Department of Pulmonology, Budapest, Hungary
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
20
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Changing of viral load of SARS-CoV2, Changes in immunglobulin G COVID-19 antibody titer, Changes at the cytokine pattern, Intensive Care Unit Admission, Length of hospital stay, Duration of mechanical ventilation, Clinical Status, Mortality
|
NCT04357106
|
COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma |
Recruiting |
Phase 2 |
Apr/13/2020 |
Aug/01/2020 |
- Acronym - COPLA
- Alternative id -
CHMI-030420-01
- Interventions -
Biological: Convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Centro de Hematología y Medicina Interna, Puebla, Mexico
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
10
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Lung injury, Overall survival, Adverse reactions to plasma
|
NCT04340050
|
COVID-19 Convalescent Plasma |
Completed |
Early Phase 1 |
Apr/10/2020 |
Dec/23/2020 |
- Alternative id -
IRB20-0523
- Interventions -
Biological: anti-SARS-CoV-2 convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
University of Chicago Medicine, Chicago, Illinois, United States
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
10
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Feasibility of performing study pathway consisting of consenting convalescent donors, harvesting convalescent plasma, application for FDA eIND and administering convalescent plasma to the patients, Type of respiratory support, Cardiac arrest, Transfer to ICU, ICU mortality, ICU length of stay, Hospital mortality, Hospital length of stay, Ventilator-free days, Overall survival (28-day mortality)
|
NCT04343261
|
Convalescent Plasma in the Treatment of COVID 19 |
Completed |
Phase 2 |
Apr/10/2020 |
Aug/13/2020 |
- Alternative id -
SFH-20-23
- Interventions -
Biological: Convalescent Plasma
- Study type - Interventional
- Study results -
Has Results
- Study locations -
Trinity Health Of New England, Hartford, Connecticut, United States
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
48
- Age -
18 Years to 90 Years (Adult, Older Adult)
- Outcome measures -
Mortality, Viral Load, Serum Antibody Titers
|
NCT04390178
|
Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19) |
Completed |
Phase 1|Phase 2 |
Apr/10/2020 |
Dec/31/2020 |
- Alternative id -
CP1
- Interventions -
Biological: SARS-CoV-2 convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Danderyd Hospital, Danderyd, Sweden
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
10
- Age -
18 Years to 80 Years (Adult, Older Adult)
- Outcome measures -
Disease progression, Adverse events (AE), Time ro resolution of fever and symptoms, Clearance of viraemia, Inflammatory parameter C-reactive protein (CRP), Inflammatory parameter white blood cell count, Inflammatory parameter haemoglobin (Hb), Inflammatory parameter Pro-calcitonin, Inflammatory parameter Creatine Kinase, Antibody response to SARS-CoV-2
|
NCT04343755
|
Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection |
Active, not recruiting |
Phase 2 |
Apr/09/2020 |
Apr/01/2022 |
- Alternative id -
Pro2020-0375
- Interventions -
Biological: Convalescent Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Hackensack University Medical Center, Hackensack, New Jersey, United States
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
52
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
For patients hospitalized for COVID-19 but not intubated, Primary objective for patients with COVID-19 already intubated, Duration of hospitalization, Duration of mechanical ventilation, Time to symptoms resolution, Overall survival, Rate of virologic clearance by nasopharyngeal swab at day 10, Impact of donor titers level on efficacy, Impact of donor titers level on safety, Recipient Anti-SARS-CoV2 titer assessment on days 0 (pre-infusion),3,10,30, 60
|
NCT04344535
|
Convalescent Plasma vs. Standard Plasma for COVID-19 |
Terminated |
Phase 1|Phase 2 |
Apr/08/2020 |
Feb/01/2021 |
- Alternative id -
SBU-COVID19-ConvalescentPlasma
- Interventions -
Biological: Convalescent Plasma, Biological: Standard Donor Plasma
- Study type - Interventional
- Study results -
Has Results
- Study locations -
Stony Brook University Hospital, Stony Brook, New York, United States
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor), Primary Purpose: Treatment
- Enrollment -
82
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
28 Day Ventilator Free Days, 90 Day All-cause Mortality
|
NCT04342182
|
Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study) |
Active, not recruiting |
Phase 2|Phase 3 |
Apr/08/2020 |
Jul/31/2021 |
- Acronym - ConCoVid-19
- Alternative id -
NL73489.078.20
- Interventions -
Biological: Convalescent plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands; NoordWest Ziekenhuisgroep, Alkmaar, Netherlands; Onze Lieve Vrouwen Gasthuis, Amsterdam, Netherlands; Rijnstate Ziekenhuis, Arnhem, Netherlands; Reinier de Graaf Gasthuis, Delft, Netherlands; Haaglanden Medisch Centrum, Den Haag, Netherlands; Catharina Ziekenhuis, Eindhoven, Netherlands; Medisch Spectrum Twente, Enschede, Netherlands; Groene Hart Ziekenhuis, Gouda, Netherlands; Martini Hospital, Groningen, Netherlands; Spaarna Gasthuis, Haarlem, Netherlands; Alrijne Ziekenhuis, Leiderdorp, Netherlands; Sint Antonius Ziekenhuis, Nieuwegein, Netherlands; Canisius-Wilhelmina Hospital, Nijmegen, Netherlands; Maasstad Ziekenhuis, Rotterdam, Netherlands; ZorgSaam Hospital, Terneuzen, Netherlands; Bernhoven Hospital, Uden, Netherlands; VieCuri, Venlo, Netherlands
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
426
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Overall mortality until discharge from the hospital or a maximum of 60 days after admission whichever comes first, Impact of 300ml convP therapy on hospital days, Impact of 300ml convP on weaning from oxygen therapy, Impact of 300ml convP on overall mortality in patients admitted to the ICU within 24 hours after admission, Difference in the effect of convP on mortality in patients with a duration of symptoms less or more the median duration of symptoms in the study population, Impact of 300ml convP therapy on ICU days in patients admitted to the ICU within 24 hours after admission, Impact of plasma therapy on the decrease in SARS-CoV2 shedding from airways, Impact of CTL and NK cell immunity on the likelihood of being protected from immune serum transfer, Safety of convP therapy, Change of the 8-point WHO COVID19 disease severity scale on day 15, Change of the 8-point WHO COVID19 disease severity scale on day 30, Change of the 8-point WHO COVID19 disease severity scale on day 15 in the subgroup of patients with a baseline neutralizing antibody titer (PRNT50) <80., Impact of plasma therapy on risk of long-term structural lung damage and lung function
|
NCT04384588
|
COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID) |
Recruiting |
Phase 2|Phase 3 |
Apr/07/2020 |
Apr/06/2021 |
- Acronym - FALP-COVID
- Alternative id -
FALP 001-2020
- Interventions -
Biological: Convalescent Plasma from COVID-19 donors
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Fundacion Arturo Lopez Perez, Providencia, Santiago, Chile
- Study designs -
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
100
- Age -
15 Years and older (Child, Adult, Older Adult)
- Outcome measures -
in-hospital mortality secondary to COVID-19 among patients treated with convalescent plasma, safety of the use of convalescent plasma drom COVID 19 donors, Mortality at 30 days, 90 days, 6 months and 1 year, in-hospital Mortality COVID-19 related compared with non-treated population according to Chilean official reports, Number of days of hospitalization in high complexity facilities after convalescent plasma use, Number of days of hospitalization in intensive care unit after convalescent plasma use, Number of days of mechanical ventilatory support in patients after convalescent plasma use, Total number of days of mechanical ventilatory support, Total number of hospitalization days in patients treated with convalescent plasma, Number of hospitalization days in patients after treatment with convalescent plasma, Viral load measuring, Immunological response in treated patients (COVID19-Immunoglobulin M and Immunoglobulin G, neutralizing antibodies), Negativization of COVID 19 load since convalescent plasma use, Negativization of COVID 19 load since hospitalization, Negativization of COVID 19 load since first reported symptoms COVID-19 related, Donor Interferon Gamma profile characterization, Donor Granulocyte Macrophage Colony Stimulating Factor characterization, Donor Tumor Necrosis Factor Alfa characterization, Donor Interleukin -1 beta characterization, Donor Interleukin-2 characterization, Donor Interleukin-4 characterization, Donor Interleukin-6 characterization, Donor Interleukin-8 characterization, Donor Interleukin-10 characterization, Receptor Interferon Gamma profile characterization, Receptor Granulocyte Macrophage Colony Stimulating Factor characterization, receptor Tumor Necrosis Factor Alfa characterization, receptor Interleukin -1 beta characterization, Receptor Interleukin-2 characterization, Receptor Interleukin-4 characterization, Receptor Interleukin-6 characterization, Receptor Interleukin-8 characterization, Receptor Interleukin-10 characterization
|
NCT04345523
|
Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients |
Completed |
Phase 2 |
Apr/03/2020 |
Apr/05/2021 |
- Acronym - ConPlas-19
- Alternative id -
ConPlas-19
- Interventions -
Other: Blood and derivatives., Drug: Standard of Care
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Hospital Clínico Universitario Lozano Blesa, Zaragoza, Aragón, Spain; Hospital Universitario Mútua Terrassa, Terrassa, Barcelona, Spain; Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain; Hospital General de Albacete, Albacete, Spain; Hospital del Mar, Barcelona, Spain; Hospital General Universitario de Ciudad Real, Ciudad Real, Spain; Hospital Universitario Donostia, Donostia, Spain; Hospital Doctor Josep Trueta, Girona, Spain; Hospital Doctor Negrín, Las Palmas, Spain; Complejo Asistencial Universitario de León, León, Spain; Hospital Universitario Arnau de Vilanova, Lleida, Spain; Hospital San Pedro, Logroño, Spain; Hospital Universitario La Princesa, Madrid, Spain; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario HM Sanchinarro, Madrid, Spain; Hospital Sant Joan de Deu de Manresa. Fundación Althaia, Manresa, Spain; Hospital Universitario de Asturias, Oviedo, Spain; Hospital Universitario Son Espases, Palma De Mallorca, Spain; Clínica Universidad de Navarra (CUN). Sedes Pamplona y Madrid, Pamplona, Spain; Complejo Hospitalario de Navarra, Pamplona, Spain; Hospital Universitario de Salamanca, Salamanca, Spain; Hospital Universitario Marqués de Valdecilla, Santander, Spain; Complejo Hospitalario de Toledo, Toledo, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital Clínico Universitario de Valladolid, Valladolid, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
350
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Category Changes in the "7-Ordinal Scale", Time to category 5, 6 or 7 of the " 7-Ordinal scale", Time to an improvement of one category from admission in the "7-Ordinal scale", Status at day 30 in the "11-Ordinal scale", Status at day 15 and 30 in the "11-Ordinal scale", Time to first deterioration, Mean change in the ranking in the "7-Ordinal scale" from baseline to days 3,5,8,11,15,29 and 60, Mean change in the ranking in the "11-Ordinal scale from baseline to days 3,5,8,11,15,29 and 60., Mortality of any cause at 15 days, Mortality of any cause at 28 days (day 29), Mortality of any cause at 60 days, Oxygenation free days, Ventilator free days, Duration of hospitalization (days), Infusion-related adverse events, Incidence of Treatment-Emergent Adverse Events, Antibodies levels in CP donors recovered from COVID-19, Viral load, Incidence of thrombotic arterial events, Incidence of thrombotic venous events, rate of rehospitalizations
|
NCT04441424
|
Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients |
Completed |
Not Applicable |
Apr/03/2020 |
Jun/01/2020 |
- Alternative id -
CPT-COVID-19
- Interventions -
Biological: Convalescent plasma, Drug: Hydroxychloroquin with Azithromycin
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Akarkh Healt hdirectorate, Baghdad, Iraq
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
49
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Death versus survival of treated patients, The length of stay in hospitals
|
NCT04492501
|
Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan |
Completed |
Not Applicable |
Apr/01/2020 |
Jul/20/2020 |
- Alternative id -
Sultan Mehmood Kamran 3
- Interventions -
Procedure: Therapeutic Plasma exchange, Biological: Convalescent Plasma, Drug: Tocilizumab, Drug: Remdesivir, Biological: Mesenchymal stem cell therapy
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan
- Study designs -
Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
600
- Age -
18 Years to 90 Years (Adult, Older Adult)
- Outcome measures -
survival, duration of hospitalization, Time to resolution of cytokine release storm, Time of viral clearance, Complications
|
NCT04333251
|
Study Testing Convalescent Plasma vs Best Supportive Care |
Not yet recruiting |
Phase 1 |
Apr/01/2020 |
Dec/31/2022 |
- Alternative id -
020-123
- Interventions -
Biological: high-titer anti-Sars-CoV-2 plasma, Other: oxygen therapy
- Study type - Interventional
- Study results -
No Results Available
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
115
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
reduction in oxygen and ventilation support
|
NCT05046652
|
Effectiveness of Convalescent Plasma Therapy in 8 Non-Intubated COVID-19 Patients in Indonesia: A Case Series |
Completed |
|
Apr/01/2020 |
Dec/31/2020 |
- Alternative id -
0408087106
- Interventions -
Biological: Convalescent Plasma Therapy
- Study type - Observational
- Study results -
No Results Available
- Study locations -
Theresia Monica Monica, Bandung, West Java, Indonesia
- Study designs -
Observational Model: Case-Only, Time Perspective: Retrospective
- Enrollment -
8
- Age -
Child, Adult, Older Adult
- Outcome measures -
Patients with two doses of CP tended to have faster recovery than those with one dose of CP., Patients with two doses of CP tended to have faster PCR negative conversion time than those with one dose of CP
|
NCT04325672
|
Convalescent Plasma to Limit Coronavirus Associated Complications |
Withdrawn |
Phase 2 |
Apr/01/2020 |
Dec/31/2022 |
- Alternative id -
20-002864
- Interventions -
Biological: Convalescent Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Basic Science
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
RNA in SARS-CoV-2, ICU Admissions, Hospital Mortality, Hospital Length of Stay (LOS), Type of respiratory support, Duration of respiratory support
|
NCT04389944
|
Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19 |
Completed |
Not Applicable |
Mar/31/2020 |
Jun/30/2020 |
- Alternative id -
Req-2020-00508; me20khanna2
- Interventions -
Other: convalescent plasma application to SARS-CoV-2 infected patients
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Blutspendezentrum SRK beider Basel, University Hospital Basel, Basel, Switzerland
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
15
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Serious adverse events in convalescent plasma treated patients, Virologic clearance in nasopharyngeal swab of convalescent plasma treated patients, Transfer to ICU, in-hospital death, Virologic clearance in plasma of convalescent plasma treated patients, Time to discharge from hospital after enrolment, Humoral immune response
|
NCT05247307
|
Efficacy of the Infusion of Donor Plasma in COVID-19 Infection |
Terminated |
Phase 3 |
Mar/31/2020 |
Dec/31/2021 |
- Alternative id -
SARS VOC 2 GALDAKAO 02
- Interventions -
Biological: convalescent plasma infusion covid 19
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Hospital Galdakao-Usansolo, Galdakao, Bizkaia, Spain
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Triple (Participant, Care Provider, Investigator), Primary Purpose: Treatment
- Enrollment -
93
- Age -
65 Years and older (Older Adult)
- Outcome measures -
Rate of hospital admission, Rate of severity of the disease, Rate of of deaths, Rate of complications
|
NCT04327349
|
Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial |
Unknown status |
Not Applicable |
Mar/28/2020 |
Sep/30/2020 |
- Alternative id -
IR.MAZUMS.REC.1399.7330, IRCT20181104041551N1
- Interventions -
Biological: Convalescent Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran, Islamic Republic of
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
30
- Age -
30 Years to 70 Years (Adult, Older Adult)
- Outcome measures -
Mortality changes in day 10, Mortality changes in day 30, Changes of C-reactive protein, Changes of Interleukin 6, Changes of tumor necrosis factor-α, Changes of PaO2/FiO2 Ratio, Changes of CD3, Changes of CD4, Changes of CD8, Changes of CD4/CD8 ratio, Changes of lymphocyte count, Changes of leukocyte count, Changes of alanine transaminase (ALT), Changes of aspartate transaminase (AST), Changes of alkaline phosphatase (ALP), Changes of lactate dehydrogenase (LDH), Changes of creatine phosphokinase (CPK), Changes of Creatine kinase-MB (CK-MB), Changes of Specific IgG, Radiological findings, Number of days ventilated, Length of hospitalization
|
NCT04554992
|
Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019) |
Active, not recruiting |
Phase 1 |
Mar/20/2020 |
Jun/01/2022 |
- Alternative id -
00025121
- Interventions -
Biological: COVID 19 Convalescent Plasma
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Houston Methodist Hopsital, Houston, Texas, United States
- Study designs -
Allocation: N/A, Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
350
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
Cumulative incidence of serious adverse events related to the treatment intervention., Mortality at Day 28 post-hospital admission., Length of hospital stay, Length of supplemental oxygen requirement., Length of mechanical ventilation requirement., Length of ICU stay
|
NCT04381936
|
Randomised Evaluation of COVID-19 Therapy |
Recruiting |
Phase 2|Phase 3 |
Mar/19/2020 |
Nov/01/2032 |
- Acronym - RECOVERY
- Alternative id -
NDPHRECOVERY, 2020-001113-21, ISRCTN50189673
- Interventions -
Drug: Lopinavir-Ritonavir, Drug: Corticosteroid, Drug: Hydroxychloroquine, Drug: Azithromycin, Biological: Convalescent plasma, Drug: Tocilizumab, Biological: Immunoglobulin, Drug: Synthetic neutralising antibodies, Drug: Aspirin, Drug: Colchicine, Drug: Baricitinib, Drug: Anakinra, Drug: Dimethyl fumarate, Drug: High Dose Corticosteroid, Drug: Empagliflozin, Drug: Sotrovimab
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
Kumasi Center for Collaborative Research in Tropical Medicine KNUST, Kumasi, Ghana; Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases, New Delhi, India; Eijkman Oxford Clinical Research Unit (EOCRU), Eijkman Institute for Molecular Biology, Jakarta, Indonesia; Clinical Trial Unit, Oxford University Clinical Research Unit-Nepal, Patan Academy of Health Sciences, Kathmandu, Nepal; Wits Health Consortium, Johannesburg, South Africa; RECOVERY Sri Lanka & Pakistan, National Intensive Care Surveillance - M.O.R.U, Colombo, Sri Lanka; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Oxford University Clinical Research Unit, Centre for Tropical Medicine, Ho Chi Minh City, Vietnam
- Study designs -
Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
50000
- Age -
Child, Adult, Older Adult
- Outcome measures -
All-cause mortality, Duration of hospital stay, Composite endpoint of death or need for mechanical ventilation or ECMO
|
NCT04348656
|
CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1) |
Terminated |
Phase 3 |
Mar/14/2020 |
Jun/16/2021 |
- Acronym - CONCOR-1
- Alternative id -
CONCOR-1
- Interventions -
Biological: Convalescent plasma
- Study type - Interventional
- Study results -
Has Results
- Study locations -
Brooklyn Hospital, Brooklyn, New York, United States; Lower Manhattan Hospital, New York, New York, United States; Weill Cornell Medical Center, New York, New York, United States; Hospital Universitário Antônio Pedro (HUAP), Niterói, Brazil; Hemario, Rio De Janeiro, Brazil; Peter Lougheed Center, Calgary, Alberta, Canada; Foothills Medical Centre, Calgary, Alberta, Canada; Rockyview General Hospital, Calgary, Alberta, Canada; University of Alberta - Royal Alexandra Hospital, Edmonton, Alberta, Canada; University of Alberta Hospital, Edmonton, Alberta, Canada; Sturgeon Community Hospital, St. Albert, Alberta, Canada; Fraser Health Authority - Abbotsford Regional Hospital and Cancer Centre, Abbotsford, British Columbia, Canada; Vancouver General Hospital, Vancouver, British Columbia, Canada; St. Paul's Hospital, Vancouver, British Columbia, Canada; Royal Jubilee Hospital, Victoria, British Columbia, Canada; Victoria General Hospital, Victoria, British Columbia, Canada; St. Boniface General Hospital, Winnipeg, Manitoba, Canada; Health Sciences Centre Winnipeg, Winnipeg, Manitoba, Canada; Grace General Hospital, Winnipeg, Manitoba, Canada; Vitalité Health Network - Acadie-Bathurst, Bathurst, New Brunswick, Canada; Vitalité Health Network - Restigouche, Campbellton, New Brunswick, Canada; Vitalité Health Network- Northwest, Edmundston, New Brunswick, Canada; Dr. Georges-L.-Dumont University Hospital Centre, Moncton, New Brunswick, Canada; Lakeridge Health Ajax Pickering, Ajax, Ontario, Canada; Hamilton General Hospital, Hamilton, Ontario, Canada; Juravinski Hospital, Hamilton, Ontario, Canada; St. Joseph's Healthcare, Hamilton, Ontario, Canada; Grand River Hospital, Kitchener, Ontario, Canada; St. Mary's Hospital, Kitchener, Ontario, Canada; London Health Sciences Centre - University Hospital, London, Ontario, Canada; Victoria Hospital, London, Ontario, Canada; Markham Stouffville Hospital, Markham, Ontario, Canada; Trillium Health Partners - Mississauga Hospital, Mississauga, Ontario, Canada; Trillium Health Partners - Credit Valley, Mississauga, Ontario, Canada; North York General Hospital, North York, Ontario, Canada; Lakeridge Health Oshawa, Oshawa, Ontario, Canada; Ottawa Hospital - General Campus, Ottawa, Ontario, Canada; Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada; Queensway Carleton Hospital, Ottawa, Ontario, Canada; Bluewater Health, Sarnia, Ontario, Canada; Scarborough Health Network, Centenary Hospital, Scarborough, Ontario, Canada; Scarborough Health Network, General Hospital, Scarborough, Ontario, Canada; Scarborough Health Network, Birchmount Hospital, Scarborough, Ontario, Canada; Niagara Health System - St. Catherines, St. Catherines, Ontario, Canada; Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Unity Health St. Michael's Hospital, Toronto, Ontario, Canada; Sinai Health System, Toronto, Ontario, Canada; Toronto General Hospital, Toronto, Ontario, Canada; Toronto Western Hospital, Toronto, Ontario, Canada; Unity Health, St. Joseph's Health Care Centre, Toronto, Ontario, Canada; Windsor Regional Hospital - Metropolitan Campus, Windsor, Ontario, Canada; Windsor Regional Hospital - Ouellette Campus, Windsor, Ontario, Canada; L'Hopital Chicoutimi, Chicoutimi, Quebec, Canada; Hôpital de la Cité-de-la-Santé, Laval, Quebec, Canada; Hôpital Charles-Le Moyne, Longueuil, Quebec, Canada; Hotel Dieu Hospital of Lévis, Lévis, Quebec, Canada; Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada; Centre hospitalier de l'Université de Montréal, Montréal, Quebec, Canada; Montréal General Hospital, Montréal, Quebec, Canada; Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec, Canada; Jewish General Hospital, Montréal, Quebec, Canada; McGill University Health Centre, Montréal, Quebec, Canada; Hôpital du Sacré-Coeur de Montreal, Montréal, Quebec, Canada; Centre Hospitalier Universitaire (CHU) de Québec - Université Laval, Quebec City, Quebec, Canada; Institut Universitaire de cardiologie et pneumologie de Québec, Quebec City, Quebec, Canada; Centre hospitalier régional de St-Jérôme, Saint-Jérôme, Quebec, Canada; Centre Hospitalier Universitaire de Sherbrooke (CHUS) - Hôpital Hôtel-Dieu, Sherbrooke, Quebec, Canada; Centre Hospitalier Universitaire de Sherbrooke (CHUS) - Hôpital Fleurimont, Sherbrooke, Quebec, Canada; Centre hospitalier affilié universitaire régional de Trois-Rivières, Trois-Rivières, Quebec, Canada; Regina General Hospital, Regina, Saskatchewan, Canada; Pasqua Hospital, Regina, Saskatchewan, Canada; St. Paul's Hospital, Saskatoon, Saskatchewan, Canada; Royal University Hospital, Saskatoon, Saskatchewan, Canada
- Study designs -
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
940
- Age -
16 Years and older (Child, Adult, Older Adult)
- Outcome measures -
Number of Participants Who Were Intubated or Died, Time to Intubation or In-hospital Death, Ventilator-free Days by Day 30, Death by Day 30, Length of Stay in Intensive Care Unit (ICU), Need for Renal Replacement Therapy, Need for Extracorporeal Membrane Oxygenation (ECMO), Development of Myocarditis, In-hospital Death, Time to In-hospital Death, Length of Stay in Hospital, Number of Participants With Grade 3 and 4 Serious Adverse Events, Number of Participants With CCP Transfusion-associated Adverse Events (AE), Number of Participants With Grade 3, 4, or 5 Serious Adverse Events, Patient Reported Outcome Using Change in EQ-5D-5L Score, Patient Reported Outcome- Quality-adjusted Life Days, Cost of Intervention and Hospital Stay
|
NCT04292340
|
Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19 |
Unknown status |
|
Feb/01/2020 |
Dec/31/2020 |
- Alternative id -
Anti-SARS-CoV-2
- Study type - Observational
- Study results -
No Results Available
- Study locations -
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
- Study designs -
Observational Model: Case-Only, Time Perspective: Prospective
- Enrollment -
15
- Age -
Child, Adult, Older Adult
- Outcome measures -
The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 1, The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3, The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7, Numbers of participants with different Clinical outcomes, Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
|
NCT04616976
|
COVID-19 With Convalescent Plasma |
Completed |
|
Jan/01/2020 |
Nov/01/2020 |
- Alternative id -
COVID-19 convalescent plasma
- Interventions -
Biological: convalescent plasma
- Study type - Observational
- Study results -
No Results Available
- Study locations -
Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China
- Study designs -
Observational Model: Case-Control, Time Perspective: Retrospective
- Enrollment -
78
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
28-day mortality, SARS-CoV-2 negative conversion rate
|
NCT02735707
|
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia |
Recruiting |
Phase 3 |
Apr/11/2016 |
Dec/01/2025 |
- Acronym - REMAP-CAP
- Alternative id -
U1111-1189-1653, 2015-002340-14, 602525, 16/631, APP1101719, 158584
- Interventions -
Drug: Ceftriaxone, Drug: Moxifloxacin or Levofloxacin, Drug: Piperacillin-tazobactam, Drug: Ceftaroline, Drug: Amoxicillin-clavulanate, Drug: Standard course macrolide, Drug: Extended course macrolide, Other: No systemic corticosteroid, Drug: Fixed-duration Hydrocortisone, Drug: Shock-dependent hydrocortisone, Drug: Fixed-duration higher dose Hydrocortisone, Other: No antiviral agent for influenza, Drug: Five-days oseltamivir, Drug: Ten-days oseltamivir, Other: No antiviral agent for COVID-19, Drug: Lopinavir / Ritonavir, Drug: Hydroxychloroquine, Drug: Hydroxychloroquine + lopinavir/ritonavir, Drug: Ivermectin, Other: No immune modulation for COVID-19, Drug: Interferon beta-1a, Drug: Anakinra, Drug: Tocilizumab, Drug: Sarilumab, Drug: Local standard venous thromboprophylaxis, Drug: Therapeutic anticoagulation, Drug: Conventional low dose thromboprophylaxis, Drug: Intermediate dose thromboprophylaxis, Drug: Continuation of therapeutic dose anticoagulation, Other: No immunoglobulin, Biological: Convalescent plasma, Biological: Delayed administration of convalescent plasma, Other: No vitamin C, Drug: Vitamin C, Other: No antiplatelet, Drug: Aspirin, Drug: P2Y12 inhibitor, Other: No simvastatin, Drug: Simvastatin, Other: Placebo, Drug: Eritoran, Drug: Apremilast, Procedure: Clinician-preferred mechanical ventilation strategy, Procedure: Protocolised mechanical ventilation strategy, Other: No renin-angiotensin system inhibitor, Drug: Angiotensin converting enzyme inhibitor, Drug: Angiotensin Receptor Blockers, Drug: ARB + DMX-200, Other: No cysteamine, Drug: Cysteamine
- Study type - Interventional
- Study results -
No Results Available
- Study locations -
University of Florida, Jacksonville, Florida, United States; Augusta University, Augusta, Georgia, United States; University of Illinois Health, Chicago, Illinois, United States; Tulane Medical Center, New Orleans, Louisiana, United States; University of Michigan, Ann Arbor, Michigan, United States; Memorial Sloan Kettering Cancer Center, New York, New York, United States; Wake Forest Baptist Health, Winston-Salem, North Carolina, United States; The Ohio State University Wexner Medical Center, Columbus, Ohio, United States; Oregon Health and Science University, Portland, Oregon, United States; University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States; Brown University - Rhode Island Hospital, Providence, Rhode Island, United States; Canberra Hospital, Canberra, Australian Capital Territory, Australia; Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia; Blacktown Hospital, Blacktown, New South Wales, Australia; Campbelltown Hospital, Campbelltown, New South Wales, Australia; Sutherland Hospital, Caringbah, New South Wales, Australia; Concord Hospital, Concord, New South Wales, Australia; Dubbo Base Hospital, Dubbo, New South Wales, Australia; Northern Beaches Hospital, Frenchs Forest, New South Wales, Australia; Nepean Hospital, Kingswood, New South Wales, Australia; St. George Hospital, Kogarah, New South Wales, Australia; Liverpool Hospital, Liverpool, New South Wales, Australia; John Hunter Hospital, Newcastle, New South Wales, Australia; Orange Health Service, Orange, New South Wales, Australia; St Vincent's Hospital Sydney, Sydney, New South Wales, Australia; Prince of Wales Hospital, Sydney, New South Wales, Australia; Royal Prince Alfred Hospital, Sydney, New South Wales, Australia; Royal North Shore Hospital, Sydney, New South Wales, Australia; Wollongong Hospital, Sydney, New South Wales, Australia; Wagga Wagga Base Hospital, Wagga Wagga, New South Wales, Australia; Westmead Hospital, Westmead, New South Wales, Australia; Royal Darwin Hospital,, Darwin, Northern Territory, Australia; Sunshine Coast University Hospital, Birtinya, Queensland, Australia; The Prince Charles Hospital, Brisbane, Queensland, Australia; Mater Hospital Brisbane, Brisbane, Queensland, Australia; Princess Alexandra Hospital, Brisbane, Queensland, Australia; Caboolture Hospital, Caboolture, Queensland, Australia; Queen Elizabeth II Jubilee Hospital, Coopers Plains, Queensland, Australia; Logan Hospital, Logan, Queensland, Australia; Redcliffe Hospital, Redcliffe, Queensland, Australia; Rockhampton Hospital, Rockhampton, Queensland, Australia; Gold Coast University Hospital, Southport, Queensland, Australia; Toowoomba Hospital, Toowoomba, Queensland, Australia; Townsville Hospital, Townsville, Queensland, Australia; Royal Adelaide Hospital, Adelaide, South Australia, Australia; The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Lyell McEwin Hospital, Adelaide, South Australia, Australia; Flinders Medical Centre, Bedford Park, South Australia, Australia; Launceston Hospital, Launceston, Tasmania, Australia; Ballarat Base Hospital, Ballarat, Victoria, Australia; Bendigo Hospital, Bendigo, Victoria, Australia; Casey Hospital, Berwick, Victoria, Australia; Box Hill Hospital, Box Hill, Victoria, Australia; Monash Medical Centre, Clayton, Victoria, Australia; Dandenong Hospital, Dandenong, Victoria, Australia; Angliss Hospital, Ferntree Gully, Victoria, Australia; Footscray Hospital, Footscray, Victoria, Australia; University Hosptial Geelong, Geelong, Victoria, Australia; The Alfred Hospital, Melbourne, Victoria, Australia; Royal Melbourne Hospital, Melbourne, Victoria, Australia; St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia; Maroondah Hospital, Ringwood East, Victoria, Australia; Sunshine Hospital, Sunshine, Victoria, Australia; Werribee Mercy Hospital, Werribee, Victoria, Australia; St John of God Hospital Midland, Midland, Western Australia, Australia; St John of God Hospital Murdoch, Murdoch, Western Australia, Australia; Royal Perth Hospital, Perth, Western Australia, Australia; Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; Fiona Stanley Hospital, Perth, Western Australia, Australia; St John of God Subiaco, Subiaco, Western Australia, Australia; AZ Sint-Jan, Brugge, Belgium; CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium; Universitair Ziekenhuis Antwerp, Edegem, Belgium; Universitair Ziekenhuis Gent, Gent, Belgium; Foothills Medical Centre, Calgary, Alberta, Canada; Peter Lougheed Centre, Calgary, Alberta, Canada; Rockyview General Hospital, Calgary, Alberta, Canada; South Health Campus, Calgary, Alberta, Canada; Royal Alexandra Hospital, Alberta, Edmonton, Alberta, Canada; University of Alberta Hospital, Edmonton, Alberta, Canada; Surrey Memorial Hospital, Surrey, British Columbia, Canada; St Boniface General Hospital, Winnipeg, Manitoba, Canada; Health Sciences Centre Winnipeg, Winnipeg, Manitoba, Canada; Grace Hospital, Winnipeg, Manitoba, Canada; Dr. Everett Chalmers Regional Hospital, Fredericton, New Brunswick, Canada; The Moncton Hospital, Fredericton, New Brunswick, Canada; The Saint John General Hospital, Fredericton, New Brunswick, Canada; William Osler Health System, Brampton, Ontario, Canada; Brantford General Hospital, Brantford, Ontario, Canada; Hamilton general Hospital, Hamilton, Ontario, Canada; Juravinski Hospital, Hamilton, Ontario, Canada; St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada; Kingston Health Sciences Centre, Kingston, Ontario, Canada; Grand River Hospital, Kitchener, Ontario, Canada; St Mary's General Hospital, Kitchener, Ontario, Canada; The Ottawa Hospital, Ottawa, Ontario, Canada; Niagara Health, Saint Catharines, Ontario, Canada; Thunder Bay General Hospital, Thunder Bay, Ontario, Canada; Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; St. Michael's Hospital Unity Health Toronto, Toronto, Ontario, Canada; Mount Sinai Hospital, Toronto, Ontario, Canada; Toronto General Hospital, Toronto, Ontario, Canada; Toronto Western Hospital, Toronto, Ontario, Canada; St Joseph's Health Centre, Toronto, Ontario, Canada; CIUSS Chaudieres-Appalaches (Levis), Lévis, Quebec, Canada; Hospital Maisonneuve-Rosemont, Montréal, Quebec, Canada; Hôpital Fleury, Montréal, Quebec, Canada; Centre Hospitalier de l'Universite de Montreal, Montréal, Quebec, Canada; McGill University Health Centre, Montréal, Quebec, Canada; Hopital du Sacre-Coeur de Montreal, Montréal, Quebec, Canada; CHU de Québec - Université Laval, Québec, Quebec, Canada; IUCPQ-UL, Québec, Quebec, Canada; Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Quebec, Canada; Regina General Hospital, Saskatoon, Saskatchewan, Canada; Universidad de La Sabana, Chía, Cundinamarca, Colombia; General County Hospital Požega, Požega, Croatia; University Hospital Centre Zagreb, Zagreb, Croatia; University Hospital for Infectious Diseases, Zagreb, Croatia; Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany; Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany; Vivantes Klinikum Neukölln, Berlin, Germany; Universitätsklinikum Köln, Cologne, Germany; Universitätsklinikum Frankfurt, Frankfurt, Germany; University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany; Medizinische Hochschule Hannover, Hannover, Germany; Universitätsklinikum Jena, Jena, Germany; Universitätsklinikum Leipzig, Leipzig, Germany; Universitäts Klinikum Tübingen, Tübingen, Germany; Universitätsklinikum Würzburg, Würzburg, Germany; Jósa András County Hospital, Nyíregyháza, Hungary; Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary; Almási Balogh Pál Kórház, Ózd, Hungary; Apollo Main Hospital, Chennai, Tamil Nadu, India; Apollo First Med Hospital, Chennai, Tamil Nadu, India; Apollo Vanagaram Hospital, Chennai, Tamil Nadu, India; Apollo Speciality Hospital - OMR, Chennai, Tamil Nadu, India; Beaumont Hospital, Dublin, Ireland; St. Vincent's University Hospital, Dublin, Ireland; University Hospital Galway, Galway, Ireland; St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; Yokohama City University Hospital, Yokohama, Kanagawa, Japan; St. Marianna University Yokohama City Seibu Hospital, Yokohama, Kanagawa, Japan; Saiseikai Kumamoto Hospital, Minami, Kumamoto, Japan; Osaka City General Hospital, Osaka, Japan; Nerima Hikarigaoka Hospital, Tokyo, Japan; Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan; Itabashi Chuo Medical Center, Tokyo, Japan; Tokyo bay Urayasu-Ichikawa Medical Center, Tokyo, Japan; Wakayama Medical University, Wakayama, Japan; Chitwan Medical College, Bharatpur, Nepal; Grande International Hospital, Kathmandu, Nepal; Hospital for Advanced Medicine and Surgery (HAMS), Kathmandu, Nepal; Nepal Mediciti, Kathmandu, Nepal; Meander Medisch Centrum, Amersfoort, Netherlands; Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands; Martini Hospital Groningen, Groningen, Netherlands; University Medical Center Groningen, Groningen, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; University Medical Center Utrecht, Utrecht, Netherlands; North Shore Hospital, Auckland, New Zealand; CVICU, Auckland City Hospital, Auckland, New Zealand; DCCM, Auckland City Hospital, Auckland, New Zealand; Middlemore Hospital, Auckland, New Zealand; Christchurch Hospital, Christchurch, New Zealand; Waikato Hospital, Hamilton, New Zealand; Taranaki Base Hospital, New Plymouth, New Zealand; Rotorua Hospital, Rotorua, New Zealand; Tauranga Hospital, Tauranga, New Zealand; Wellington Regional Hospital, Wellington, New Zealand; Whangarei Hospital, Whangarei, New Zealand; Ziauddin University Hospital Clifton Campus, Karachi, Sindh, Pakistan; Abbasi Shaheed Hospital, Karachi, Sindh, Pakistan; National Institute of Cardiovascular Diseases, Karachi, Karachi, Sindh, Pakistan; South City Hospital, Karachi, Karachi, Sindh, Pakistan; Ziauddin University North Nazimabad Campus, Karachi, Sindh, Pakistan; Centro Hospitalar do Medio Tejo, Abrantes, Portugal; Hospital Lusíadas Lisbon, Lisboa, Portugal; Clinical Hospital of Infectious and Tropical Diseases "Dr. Victor Babes", Bucharest, Romania; King Abdulaziz Medical City, Riyadh, Saudi Arabia; Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain; Hospital Universitario Reina Sofia, Córdoba, Spain; Basildon Hospital, Basildon, England, United Kingdom; Basingstoke and North Hampshire Hospital, Basingstoke, England, United Kingdom; Royal United Hospital, Bath, Bath, England, United Kingdom; Queen Elizabeth Hospital Birmingham, Birmingham, England, United Kingdom; Birmingham City Hospital, Birmingham, England, United Kingdom; Blackburn Hospital, Blackburn, England, United Kingdom; Pilgrim's Hospital, Boston, England, United Kingdom; Royal Bournemouth Hospital, Bournemouth, England, United Kingdom; Royal Sussex County Hospital, Brighton, England, United Kingdom; Southmead Hospital, Bristol, England, United Kingdom; Bristol Royal Hospital, Bristol, England, United Kingdom; Queen's Hospital, Burton, Burton on Trent, England, United Kingdom; Royal Papworth Hospital, Cambridge, England, United Kingdom; Addenbrookes Hospital, Cambridge, England, United Kingdom; Cumberland Royal Infirmary, Carlisle, England, United Kingdom; Ashford & St Peters Hospital Trust, Chertsey, England, United Kingdom; Chesterfield Royal Hospital, Chesterfield, England, United Kingdom; Countess of Chester Hospital, Chester, England, United Kingdom; Colchester Hospital, Colchester, England, United Kingdom; University Hospital Coventry, Coventry, England, United Kingdom; North Manchester General Hospital, Crumpsall, England, United Kingdom; Darlington Memorial Hospital, Darlington, England, United Kingdom; Darent Valley Hospital, Dartford, England, United Kingdom; Russells Hall Hospital, Dudley, England, United Kingdom; University Hospital of North Durham, Durham, England, United Kingdom; Royal Devon and Exeter Hospital, Exeter, England, United Kingdom; Frimley Park Hospital, Frimley, England, United Kingdom; Queen Elizabeth Hospital, Gateshead, England, United Kingdom; Medway Maritime Hospital, Gillingham, England, United Kingdom; James Paget Kings Lynn Hospital, Great Yarmouth, England, United Kingdom; Royal Surrey County Hospital, Guildford, England, United Kingdom; Northwick Park Hospital, Harrow, England, United Kingdom; Hereford County Hospital, Hereford, England, United Kingdom; Barnet Hospital, High Barnet, England, United Kingdom; Huddersfield Hospital, Huddersfield, England, United Kingdom; King George Hospital, Ilford, England, United Kingdom; Ipswich Hospital, Ipswich, England, United Kingdom; Kettering Hospital, Kettering, England, United Kingdom; Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom; Leicester Royal Infirmary, Leicester, England, United Kingdom; Glenfield Hospital, Leicester, England, United Kingdom; Lincoln County Hospital, Lincoln, England, United Kingdom; Liverpool Heart and Chest Hospital, Liverpool, England, United Kingdom; Alder Hey Hospital, Liverpool, England, United Kingdom; Royal Liverpool Hospital, Liverpool, England, United Kingdom; University Hospital Aintree, Liverpool, England, United Kingdom; Croydon University Hospital, London, England, United Kingdom; Royal London Hospital, London, England, United Kingdom; Whipps Cross Hospital, London, England, United Kingdom; Newham Hospital, London, England, United Kingdom; St Barts Hosptial, London, England, United Kingdom; North Middlesex Hospital, London, England, United Kingdom; Royal Free Hospital, London, England, United Kingdom; St Thomas' Hospital, London, England, United Kingdom; Guy's Hospital, London, England, United Kingdom; King's College Hospital, London, England, United Kingdom; St George's Hospital, London, England, United Kingdom; Royal Marsden Hospital, London, England, United Kingdom; Ryal Brompton, London, England, United Kingdom; Hammersmith Hospital, London, England, United Kingdom; St Mary's Hospital, London, England, United Kingdom; Charing Cross Hospital, London, England, United Kingdom; Luton and Dunstable University Hospital, Luton, England, United Kingdom; Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, England, United Kingdom; Manchester Royal Infirmary, Manchester, England, United Kingdom; The Christie Hospital, Manchester, England, United Kingdom; Wythenshawe Hospital, Manchester, England, United Kingdom; Queen Elizabeth Hospital, Woolwich, Margate, England, United Kingdom; The James Cook University Hospital, Middlesbrough, England, United Kingdom; Milton Keynes University Hospital, Milton Keynes, England, United Kingdom; Royal Victoria Infirmary, Newcastle, Newcastle, England, United Kingdom; Newcastle Freeman Hospital, Newcastle, England, United Kingdom; Northampton General Hospital, Northampton, England, United Kingdom; Norfolk and Norwich University Hospital, Norwich, England, United Kingdom; City Hospital Nottingham, Nottingham, England, United Kingdom; Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, England, United Kingdom; George Eliot Hospital, Nuneaton, England, United Kingdom; Royal Oldham Hospital, Oldham, England, United Kingdom; Princess Royal University Hospital, Orpington, England, United Kingdom; John Radcliffe Hospital, Oxford, England, United Kingdom; Derriford Hospital, Plymouth, England, United Kingdom; Poole Hospital NHS Foundation Trust, Poole, England, United Kingdom; Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, England, United Kingdom; Whiston Hospital, Prescot, England, United Kingdom; Royal Preston Hospital, Preston, England, United Kingdom; Royal Berkshire Hospital, Reading, England, United Kingdom; Alexandra Hospital, Redditch, Redditch, England, United Kingdom; Queen's Hospital Romford, Romford, England, United Kingdom; Rotherham General Hospital, Rotherham, England, United Kingdom; Salford Royal Hospital, Salford, England, United Kingdom; Salisbury District Hospital, Salisbury, England, United Kingdom; Royal Hallamshire Hospital, Sheffield, England, United Kingdom; Northern General Hospital, Sheffield, England, United Kingdom; Wexham Park Hospital, Slough, England, United Kingdom; South Tyneside District Hospital, South Shields, England, United Kingdom; Southampton General Hospital, Southampton, England, United Kingdom; Stepping Hill Hospital, Stockport, England, United Kingdom; University Hospital of North Tees, Stockton-on-Tees, England, United Kingdom; Royal Stoke University Hospital, Stoke-on-Trent, England, United Kingdom; Sunderland Hospital, Sunderland, England, United Kingdom; King's Mill Hospital, Sutton In Ashfield, England, United Kingdom; Great Western Hospital, Swindon, England, United Kingdom; Western General Hospital, Swindon, England, United Kingdom; Musgrove Park Hospital, Taunton, England, United Kingdom; Torbay and South Devon Hospital, Torquay, England, United Kingdom; Royal Cornwall Hospital, Truro, England, United Kingdom; Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, England, United Kingdom; Harefield Hospital, Uxbridge, England, United Kingdom; Watford General Hospital, Watford, England, United Kingdom; Southend University Hospital, Westcliff-on-Sea, England, United Kingdom; West Cumberland Hospital, Whitehaven, England, United Kingdom; Royal Albert Edward Infirmary, Wigan, England, United Kingdom; Royal Hampshire Hospital, Winchester, England, United Kingdom; Arrow Park Hospital, Wirral, England, United Kingdom; New Cross Hospital, Wolverhampton, England, United Kingdom; Worcester Royal Hospital, Worcester, England, United Kingdom; York Hospital, York, England, United Kingdom; York Hospital, York, England, United Kingdom; Antrim Area Hospital, Antrim, Northern Ireland, United Kingdom; Royal Victoria Hospital, Belfast, Belfast, Northern Ireland, United Kingdom; Mater Hospital, Belfast, Northern Ireland, United Kingdom; Belfast City Hospital, Belfast, Northern Ireland, United Kingdom; Altnagelvin Hospital, Derry, Northern Ireland, United Kingdom; Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom; Ninewells Hospital, Dundee, Scotland, United Kingdom; Royal Infirmary of Edinburgh, Edinburgh, Scotland, United Kingdom; Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom; Queen Elizabeth University Hospital, Glasgow, Glasgow, Scotland, United Kingdom; Royal Alexandra Hospital, Glasgow, Paisley, Scotland, United Kingdom; Neville Hall Hospital, Abergavenny, Wales, United Kingdom; Glan Clywd Hospital, Bodelwyddan, Wales, United Kingdom; Princess of Wales Hospital, Bridgend, Wales, United Kingdom; University Hospital of Wales, Cardiff, Wales, United Kingdom; Glangwilli Hospital, Carmarthen, Wales, United Kingdom; Grange University Hospital, Cwmbran, Wales, United Kingdom; Royal Gwent Hospital, Newport, Wales, United Kingdom; Royal Glamorgan Hospital, Pontyclun, Wales, United Kingdom; Morriston Hospital, Swansea, Wales, United Kingdom; Wrexham Maelor Hospital, Wrexham, Wales, United Kingdom
- Study designs -
Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: None (Open Label), Primary Purpose: Treatment
- Enrollment -
10000
- Age -
18 Years and older (Adult, Older Adult)
- Outcome measures -
All-cause mortality, Days alive and not receiving organ support in ICU, ICU Mortality, ICU length of stay, Hospital length of stay, Ventilator free days, Organ failure free days, Health-related Quality of life assessment, Proportion of intubated patients who receive a tracheostomy, Destination at time of hospital discharge, Readmission to the index ICU during the index hospitalization, World Health Organisation 8-point ordinal scale outcome
|
NCT04472572
|
Expanded Access to Convalescent Plasma for Treatment of COVID-19 |
Available |
|
Jan/01/1970 |
Jan/01/1970 |
- Alternative id -
Pro2020-0663
- Interventions -
Biological: Convalescent Plasma
- Study type - Expanded Access:Treatment IND/Protocol
- Study results -
No Results Available
- Study locations -
Hackensack University Medical Center, Hackensack, New Jersey, United States
- Age -
18 Years and older (Adult, Older Adult)
|
NCT05157165
|
Convalescent Plasma in Hospitalized COVID-19 Patients |
Available |
|
Jan/01/1970 |
Jan/01/1970 |
- Alternative id -
00001
- Interventions -
Biological: Convalescent plasma
- Study type - Expanded Access
- Study results -
No Results Available
- Age -
18 Years and older (Adult, Older Adult)
|
NCT04372368
|
Convalescent Plasma for the Treatment of Patients With COVID-19 |
No longer available |
|
Jan/01/1970 |
Jan/01/1970 |
- Alternative id -
20-0990
- Interventions -
Biological: COVID-19 Convalescent Plasma
- Study type - Expanded Access:Treatment IND/Protocol
- Study results -
No Results Available
- Study locations -
Children's Hospital Colorado, Aurora, Colorado, United States; University of Colorado Hospital, Aurora, Colorado, United States; UCHealth Memorial Hospital North, Colorado Springs, Colorado, United States; Denver Health Medical Center, Denver, Colorado, United States; UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States; UCHealth Highlands Ranch Hospital, Highlands Ranch, Colorado, United States
- Age -
18 Years and older (Adult, Older Adult)
|
NCT04363034
|
Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program |
Temporarily not available |
|
Jan/01/1970 |
Jan/01/1970 |
- Alternative id -
260944
- Interventions -
Biological: Convalescent Plasma
- Study type - Expanded Access:Intermediate-size Population
- Study results -
No Results Available
- Age -
18 Years and older (Adult, Older Adult)
|
NCT04374370
|
SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP) |
No longer available |
|
Jan/01/1970 |
Jan/01/1970 |
- Alternative id -
1596191
- Interventions -
Biological: SARSCoV2 Convalescent Plasma
- Study type - Expanded Access:Intermediate-size Population
- Study results -
No Results Available
- Study locations -
AdventHealth Orlando, Orlando, Florida, United States
- Age -
6 Years to 99 Years (Child, Adult, Older Adult)
|
NCT04445207
|
Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19 |
Available |
|
Jan/01/1970 |
Jan/01/1970 |
- Alternative id -
H000020420
- Interventions -
Biological: Convalescent Plasma
- Study type - Expanded Access:Treatment IND/Protocol
- Study results -
No Results Available
- Study locations -
UMass Medical School, Worcester, Massachusetts, United States
- Age -
12 Years and older (Child, Adult, Older Adult)
|
NCT04338360
|
Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19 |
Approved for marketing |
|
Jan/01/1970 |
Jan/01/1970 |
- Alternative id -
20-003312
- Interventions -
Biological: COVID-19 convalescent plasma
- Study type - Expanded Access:Intermediate-size Population
- Study results -
No Results Available
- Study locations -
Mayo Clinic in Arizona, Scottsdale, Arizona, United States; Mayo Clinic in Florida, Jacksonville, Florida, United States; Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota, United States; Mayo Clinic Health System in Austin, Austin, Minnesota, United States; Mayo Clinic Health System in Cannon Falls, Cannon Falls, Minnesota, United States; Mayo Clinic Health System in Lake City, Lake City, Minnesota, United States; Mayo Clinic Health System in Mankato, Mankato, Minnesota, United States; Mayo Clinic Health System in Owatonna, Owatonna, Minnesota, United States; Mayo Clinic Health System in Red Wing, Red Wing, Minnesota, United States; Mayo Clinic in Rochester, Rochester, Minnesota, United States; Mayo Clinic Health System - Eau Claire, Eau Claire, Wisconsin, United States; Mayo Clinic Health System - Franciscan Healthcare, La Crosse, Wisconsin, United States
- Age -
18 Years and older (Adult, Older Adult)
|
NCT04420988
|
Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients |
Available |
|
Jan/01/1970 |
Jan/01/1970 |
- Alternative id -
Pro2020000746, Pro2020000911
- Interventions -
Biological: COVID-19 Convalescent Plasma
- Study type - Expanded Access:Individual Patients|Intermediate-size Population
- Study results -
No Results Available
- Study locations -
Rutgers New Jersey Medical School, Newark, New Jersey, United States; University Hospital, Newark, New Jersey, United States
- Age -
18 Years and older (Adult, Older Adult)
|
NCT04358211
|
Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19 |
No longer available |
|
Jan/01/1970 |
Jan/01/1970 |
- Alternative id -
2020-595
- Interventions -
Biological: Biological: COVID-19 convalescent plasma
- Study type - Expanded Access:Intermediate-size Population|Treatment IND/Protocol
- Study results -
No Results Available
- Study locations -
Tulane Medical Center, New Orleans, Louisiana, United States
- Age -
18 Years and older (Adult, Older Adult)
|
NCT04360486
|
Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) |
No longer available |
|
Jan/01/1970 |
Jan/01/1970 |
- Alternative id -
S-20-02, IND 19930
- Interventions -
Biological: Anti-Sars-CoV-2 Convalescent Plasma
- Study type - Expanded Access:Treatment IND/Protocol
- Study results -
No Results Available
- Study locations -
Naval Hospital Camp Pendleton, Oceanside, California, United States; Navy Medical Center San Diego, San Diego, California, United States; USS Abraham Lincoln, San Diego, California, United States; USS Carl Vinson, San Diego, California, United States; USS Essex, San Diego, California, United States; USS Makin Island, San Diego, California, United States; USS Nimitz, San Diego, California, United States; USS Theodore Roosevelt, San Diego, California, United States; Evans Army Community Hospital, Fort Carson, Colorado, United States; Eglin Air Force Base, Eglin Air Force Base, Florida, United States; Naval Hospital Jacksonville, Jacksonville, Florida, United States; Martin Army Community Hospital, Fort Benning, Georgia, United States; Eisenhower Army Medical Center, Fort Gordon, Georgia, United States; Tripler Army Medical Center, Honolulu, Hawaii, United States; Keesler Medical Center, Biloxi, Mississippi, United States; Nellis Air Force Base, Las Vegas, Nevada, United States; Naval Medical Center Camp Lejeune, Camp Lejeune, North Carolina, United States; Wright Patterson Medical Center, Wright-Patterson Air Force Base, Ohio, United States; William Beaumont Army Medical Center, El Paso, Texas, United States; Brooke Army Medical Center, Fort Sam Houston, Texas, United States; Fort Belvoir Community Hospital, Fort Belvoir, Virginia, United States; Naval Surface Force Atlantic, Norfolk, Virginia, United States; USS Dwight D. Eisenhower, Norfolk, Virginia, United States; USS Gerald R. Ford, Norfolk, Virginia, United States; Naval Medical Center Portsmouth, Portsmouth, Virginia, United States; Madigan Army Medical Center, Lakewood, Washington, United States; Craig Joint Theatre Hospital Bagram AFGH, Bagram, Afghanistan; Djibouti Expeditionary Medical Facility, Djibouti, Djibouti; Landstuhl Regional Medical Center, Landstuhl, Germany; Naval Hospital Guam, Agaña, Guam; Baghdad Diplomat Support Center Iraq, Baghdad, Iraq; Misawa Air Force Base, Aomori, Japan; Yokota Air Base, Fussa, Japan; US Naval Hospital Okinawa, Okinawa, Japan; Naval Hospital Yokosuka, Yokosuka, Japan; USS America, Yokosuka, Japan; USS Ronald Reagan, Yokosuka, Japan; US Military Hospital Kuwait, Kuwait, Kuwait
- Age -
Child, Adult, Older Adult
|